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ABSTRACT 
 
Environmental factors used in consumer products or manufacturing (e.g. in plastics, detergents, 
surfactants, pesticides and industrial chemicals) are thought to have estrogenic activities. These 
xenoestrogens (XEs) are chemicals derived from a variety of natural and anthropogenic sources that can 
interfere with endogenous estrogens by either mimicking or blocking their responses via non-genomic 
and/or genomic signaling mechanisms. There is evidence and an ongoing discussion that XEs may affect 
human health, increasing the incidence of endocrine disorders and have recently emerged as a new risk 
factor for obesity and cardiovascular disease (CVD). 
In this regard, we evaluated XE (aldrin, p,p’-dichlorodiphenyldichloroethylene (p,p’-DDE), 
hexachlorobenzene (HCB), sum of hexachlorocyclohexane (∑HCH: α-HCH, β-HCH and δ-HCH), and lindane) 
levels in plasma and in adipose tissue (AT) in a sample of Portuguese obese patients that underwent 
bariatric surgery. Its putative association with metabolic and inflammatory parameters and 10-year CVD 
risk (calculated throught the Framingham Risk Score) was assessed, according to menopausal status. We 
also investigated the multiple actions of XEs (bisphenol A (BPA), di-n-butyl phthalate (DBP) and di-ethyl-2-
hexyle phthalate (DEHP)) on human monocyte-derived macrophage migration, cytokine release and 
estrogen-related signaling pathways.  
Plasma and AT (from visceral (vAT) and subcutaneous (scAT) depots) samples from obese (BMI ≥ 35 kg/m2) 
premenopausal (n=73) and postmenopausal (n=48) women were collected and the levels of XEs were 
determined by gas chromatography with electron-capture detection. Anthropometric and biochemical 
data were assessed prior to surgery. Additionally, human peripheral blood monocyte-derived 
macrophages after classical M1 (lipopolysaccharide, 100 ng/mL) or alternative M2 (IL4 (15 ng/mL)) 
activation were treated with 17β-estradiol (E2) or XE alone or in combination with selective estrogen 
receptor (ER) α or ERβ antagonists. Macrophage cytokine release, migratory capability and estrogen-
associated signaling pathways were evaluated.  
Our data show that XEs are pervasive in the samples assessed and the distribution and concentration of 
individual and total XEs differed between plasma, vAT and scAT. Furthermore, the pattern of accumulation 
was different between pre- and postmenopausal women. In premenopausal women, XEs accumulate 
preferentially in vAT and although XEs in this location showed a better correlation with metabolic 
dysfunction, plasma XEs were the best predictors of inflammation and 10-year CVD risk. We also advance 
that plasma XEs in these women may be released from vAT as consequence of local toxicity and AT 
dysfunction induced by XEs. Additionally, we observed that postmenopausal women had a worst CVD risk 
profile.  
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Aiming at assessing the interference of XEs with inflammatory cells implicated in metabolic inflammation 
and cardiometabolic risk, we demonstrated that ERs are differently expressed among different stages of 
macrophage polarization. ERα was expressed in higher levels in macrophages of either subset and most of 
the effects have been related to this isoform; however, ERβ may also play a role. All tested XEs had a 
tendency to stimulate M2 migration, an effect that followed the same direction than that of E2. E2 
significantly induced M1 release of IL10 and IL6 and decreased IL10, IL6, tumor necrosis factor (TNF)-α and 
IL1β release by M2 macrophages. Moreover, all XEs significantly induced IL10 and decreased IL6 without 
changing TNF-α release by M1 cells and globally decreased IL10, IL6, TNF-α and IL1β release by M2 
macrophages. However, DEHP and DBP significantly increased IL1β release in M1 and M2 macrophages, 
respectively.  We point out that the previous exposure to the lack/decrease of estrogen signaling, since 
these cells were obtained from postmenopausal women, may render cells to a more pro-inflammatory 
situation, which may contribute to the manifestation of chronic inflammatory actions. Most effects of E2 as 
well as of XEs were shown to be mediated by either ERα or ERβ and/or by orchestrating nuclear factor- B, 
activator protein 1, c-jun N-terminal kinase and extracellular signal-regulated kinases signaling pathways. 
This work increased the knowledge on XEs ability to mediate obesity-associated inflammation and related 
metabolic abnormalities, according to menopausal status. We advance a number of potential effects of 
XEs, highlighting the fact that their hormone-related effects are likely dependent of endogenous hormonal 
milieu. From the amount of evidence being presently accumulated, it is becoming clearer that neglecting 
the novel and emerging knowledge about XEs and metabolic disease will have significant health impacts 
for the general population, as well as on the generations to come.  
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RESUMO 
 
Diversos fatores de origem ambiental como os compostos utilizados em produtos de uso diário ou na 
indústria (por exemplo, em plásticos, detergentes, surfactantes, pesticidas e outros produtos químicos 
industriais) podem apresentar atividade estrogénica. Os xenoestrogénios (XEs) são compostos, de origem 
natural ou antropogénica, que podem interferir com a sinalização estrogénica, mimetizando ou 
bloqueando as respostas às hormonas endógenas através de mecanismos genómicos e/ou não-
genómicos. Com base na evidência científica atual, assiste-se a uma discussão sobre o impacto da 
exposição humana a XEs na saúde, sendo plausível uma associação positiva com a incidência de doenças e 
complicações endócrinas. Assim sendo, estes compostos emergiram como um novo fator de risco para a 
obesidade e para as doenças cardiovasculares.  
Por conseguinte, foram avaliados os níveis de XEs (aldrina, p,p'-diclorodifenildicloroetileno (p,p'-DDE), 
hexaclorobenzeno (HCB), somatório de hexaclorociclohexano (ΣHCH: α-HCH, β-HCH e δ-HCH), e lindano) 
no plasma e no tecido adiposo de uma amostra de indivíduos com obesidade mórbida, e doença 
metabólica associada, submetidos a cirurgia bariátrica. Avaliou-se a sua associação com parâmetros 
metabólicos e inflamatórios e o risco de desenvolver doença cardiovascular a 10 anos (calculado a partir 
do Score de Framingham) em mulheres pré- ou pós-menopausa. Por outro lado, investigaram-se os efeitos 
de diferentes XEs (bisfenol A (BPA), dibutilftalato (DBP) e dietil-2-hexilftalato (DEHP)) na capacidade de 
migração, na libertação de citocinas e nas vias de sinalização associadas aos estrogénios em macrófagos 
derivados de monócitos humanos. 
Amostras de plasma e de tecido adiposo (subcutâneo e visceral) de mulheres obesas (IMC ≥ 35 kg/m2) na 
pré- (n=73) ou pós-menopausa (n=48) foram recolhidas e os níveis de XEs foram determinados por 
cromatografia gasosa com deteção eletroquímica. Os dados antropométricos e bioquímicos foram 
avaliados no momento da cirurgia. Adicionalmente, usando um modelo simples de cultura celular, 
trataram-se com 17β-estradiol (E2) ou XEs isoladamente ou em combinação com antagonistas seletivos do 
recetor de estrogénios (ER) α ou ERβ, macrófagos derivados de monócitos do sangue periférico humano 
ativados pela via clássica M1 (lipopolissacarídeo, 100 ng/mL) ou alternativa M2 (interleucina (IL) 4, 15 
ng/mL). A libertação de citocinas, a capacidade de migração e as vias de sinalização associadas aos 
estrogénios foram avaliadas. 
Os nossos dados mostram que os XEs estão extensamente presentes nas amostras obtidas da população 
obesa estudada e o perfil individual ou total de distribuição e concentração dos XEs difere entre o plasma, 
o TAV e o TASC. Além disso, o padrão de acumulação foi diferente entre mulheres pré- e pós-menopausa. 
Nas mulheres pré-menopausa, os XEs acumulam-se preferencialmente no TAV e, ainda que o somatório 
de XEs nesta localização se correlacione com disfunção metabólica, os XEs de plasma apresentam-se como 
os melhores preditores de inflamação e de risco de doenças cardiovasculares a 10 anos. Foi também 
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proposto que os XEs no plasma destas mulheres podem ter origem no TAV, como consequência da 
toxicidade local e consequente disfunção induzida pelos XEs. Além disso, observou-se que as mulheres em 
pós-menopausa apresentavam maior prevalência de risco de cardiovascular a 10 anos. 
Com o objectivo de determinar a interferência dos XEs com as células inflamatórias implicadas na 
disfunção metabólica e no risco cardiometabólico, demonstrou-se que a transcrição do ERα e do ERβ é 
diferente de acordo com o estado de ativação dos macrófagos. O ERα foi o mais expresso nos dois 
subtipos de macrófagos, mediando a maioria dos efeitos; no entanto, o ERβ pode também desempenhar 
um papel relevante. Todos os XEs testados apresentavam uma tendência para estimular a migração dos 
macrófagos M2, mimetizando o efeito do E2. O E2 induziu significativamente a liberação de IL10 e IL6 nos 
macrófagos M1 e diminuiu a libertação de IL10, IL6, fator de necrose tumoral (TNF)-α e IL1β pelos 
macrófagos M2. Além disso, todos os XEs induziram significativamente a libertação de IL10 e diminuíram a 
de IL6 sem alterar o TNF-α nos macrófagos M1 e, globalmente, diminuíram a libertação de IL10, de IL6, de 
TNF-α e de IL1β nos macrófagos M2. No entanto, o DEHP e o DBP aumentaram significativamente a 
libertação IL1β em macrófagos M1 e M2, respetivamente. Destacamos ainda que a exposição prévia a um 
ambiente com ausência/diminuição da sinalização mediada pelos estrogénios, visto que as células foram 
obtidas de mulheres pós-menopausa, pode predispor as células a um estado mais pró-inflamatório, o que 
pode contribuir para a activação inflamatória crónica. Mostramos ainda que muitos dos efeitos atribuídos 
ao E2, bem como os efeitos dos XEs, foram mediados quer pelo ERα ou ERβ e/ou orquestrados pelas vias 
de sinalização do fator nuclear- B, da proteína de ativação 1, da cínase c-jun N-terminal e das cínases 
reguladas por sinais extracelulares. 
Este trabalho permitiu ampliar o conhecimento sobre a capacidade dos XEs mediarem a inflamação 
associada à obesidade e as complicações metabólicas com ela relacionadas, de acordo com estado de 
menopausa. São revelados diferentes efeitos possíveis dos XEs, destacando-se que os seus efeitos 
alteradores endócrinos são provavelmente dependente do ambiente hormonal endógeno. Em última 
análise, estes resultados tornam evidente que negligenciar o mais recente conhecimento sobre a relação 
dos XEs com a doença metabólica poderá ter um impacto negativo na saúde da população em geral, bem 
como nas gerações futuras. 
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INTRODUCTION 
 
Obesity and the adipose tissue  
Obesity is most definitely a multifactorial disease which is caused by a complex interaction between 
genetic, behavioral, and environmental factors. The most common causes are thought to be overeating 
high caloric diets combined with a sedentary lifestyle which is imposed on a background of genetic 
predisposition for the disease. However, these factors alone fail to solely explain the alarming rate and 
magnitude of the obesity epidemic [1]. Prevalence of obesity has increased worldwide being a source of 
concern since the negative consequences of obesity start as early as in childhood [2]. According to the 
World Health Organization (WHO), 35% of adults worldwide aged more than 20 years were overweight 
(34% men and 35% women) in 2008, including 10% of men and 14% of women being considered obese 
[3]. In Portugal, 59% of adults aged more than 20 years were overweight (64% men and 55% women) in 
2013 including 21% of obese men and 23% of obese women [4]. New hypotheses are emerging to explain 
the etiopathogenesis of this condition, including stress, immunological alterations, micronutrient deficits, 
environmental chemicals and changes in gut microbiota [5, 6].  
Increased storage of triacylglycerols leading to an expanded adipose tissue (AT) mass characterizes 
obesity. Past theories postulated that the main function of AT was the storage of energy under conditions 
of excess calories and their release in periods of fasting. Later, thermoregulation and mechanical organ 
protection were added [7]. The subsequent identification and characterization of leptin in 1994 firmly 
established AT as an endocrine organ [8]. Noteworthy, AT has been acknowledged as the largest 
endocrine organ secreting several hormones such as leptin and adiponectin, pro- and anti-inflammatory 
factors, growth factors and complement proteins, which act at both the local (autocrine/paracrine) and 
systemic (endocrine) level [9, 10]. The important endocrine function of AT is emphasized by the adverse 
metabolic consequences of both AT excess and deficiency [11]. 
 Far from being a simple organ, AT exhibits a marked heterogeneity both in terms of its anatomical 
location and in relation to its cellular composition [12]. There are two major anatomic subdivisions of AT, 
each with unique anatomic, metabolic, endocrine, paracrine, and autocrine properties: visceral (v)AT and 
subcutaneous (sc)AT. scAT stores more than 80% of total body fat in the body. The most commonly 
defined and studied subcutaneous sites of accumulation are the abdominal, gluteal and femoral depots. 
vAT is mostly associated with digestive organs, and include omental, mesenteric, and epiploic AT [13]. The 
size of each fat compartment results from the integration of the size and number of lipid-laden 
adipocytes, which represent the main cellular component of AT. However, the adipose organ is composed 
by various cell types including not only adipocytes but also a stromal vascular fraction which includes 
preadipocytes, fibroblasts, vascular endothelial cells, pericytes and different immune cells (macrophages, 
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T-cells, neutrophils, lymphocytes) [9]. These later cellular components can be separated from mature 
adipocytes by digestion and centrifugation [14]. Differences in preadipocyte populations have been 
reported, scAT containing a higher number of preadipocytes with higher proliferative capacity, which 
contributes to higher plasticity and adipogenic potential of this AT depot [15, 16], mainly in women [17]. 
In general, expansion of AT can occur either by an increase in volume of preexisting adipocytes 
(hypertrophy) or by hyperplasia in which an increase in AT occurs through recruitment of new 
preadipocytes. The association between number or size of adipocytes and obesity level is modulated as a 
function of anatomical localization and sex. Tchoukalova et al. [18] have shown that lower AT 
compartments of obese women contain more adipocytes than those of lean women, whereas obesity is 
not related to cell number in lower-body compartments in men. These results may suggest that during 
weight gain, lower-body AT tends to expand through hyperplasia in women, but through hypertrophy in 
men [19]. With regard to visceral adipocyte size and number, adipocytes are 20%-30% smaller in omental 
AT when compared to abdominal scAT in women, while they are similar in size in men [20, 21]. 
Additionally, in lean to moderately obese individuals of both sexes, a strong correlation is observed 
between abdominal subcutaneous adipocyte size and total AT, suggesting that expansion of abdominal AT 
may occur by adipocyte hypertrophy in both sexes [18]. Thus, these findings suggest that in women, 
expansion of the scAT relies more heavily on adipocyte hyperplasia than vAT, which may be 
predominantly hypertrophic [22]. On the other hand, AT cell hypertrophy or hyperplasia is influenced by 
vascular supply. In humans, scAT has higher capillary density and angiogenic growth capacity when 
compared to samples taken from the visceral depot [23]. Further, adipocyte hypertrophy is related with 
impaired AT function, whereas data linking adipocyte hyperplasia to metabolic alterations are more 
limited [24, 25]. Another interesting point is that the number of stromal cells (non-adipocytes, mainly 
macrophages) per gram of AT is greater in omental vAT than abdominal scAT [26, 27]. Thus, central 
obesity, particularly visceral obesity, but also including accumulation in abdominal scAT (apple-shaped, 
android obesity), confers increased risk for metabolic complications of obesity, whereas peripheral 
obesity, mostly accumulation in gluteofemoral region (pear-shaped, gynoid obesity), is associated with 
lower risk and may be even protective [28]. Moreover, during progression of obesity, there are changes in 
the number, phenotype, activity and location of immune, vascular and structural cells. 
 
Adipose tissue macrophages and obesity-related inflammation 
Metabolic diseases and obesity are accompanied by major alterations of AT functions such as a state of 
chronic low-grade inflammation. It is well established that during the course of obesity, when the ability of 
expansion of AT reaches the limit to accommodate the excess of nutrients, functional and morphological 
changes may occur, regulating the quantity and quality of all its cellular components, together with 
changes in adipokine secretion profile with unbalanced production of pro- and anti-inflammatory factors 
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[29-33]. These inflammatory molecules contribute to a marked disturbance of paracrine dialogues, which 
favor the alteration of AT biology. It has been highlighted that obesity-associated inflammation does not 
meet the criteria of classical inflammation [31]. In fact, inflammatory activation is often modest and local, 
being mainly triggered by metabolic surplus with metabolic specialized cells, such as adipocytes activating 
cellular stress pathways, thus initiating and sustaining the inflammatory program [31, 34, 35]. In fact, the 
number of AT macrophages (ATM) is increased in obesity which has been set into attention by the work of 
Weisberg et al. [36]. ATMs, like other macrophages, arise from a lineage that includes bone marrow 
precursors and blood monocytes [37]. Since macrophages were considered to be terminally differentiated 
cells and postmitotic [38], mechanisms of increased macrophage number in AT during obesity include 
both enhanced recruitment of blood-borne monocytes [39] by chemoattractant proteins including 
monocyte chemotactic protein (MCP)-1, chemerin, progranulin, colony stimulating factor 1 and local 
proliferation [40, 41].  
Under normal AT functioning, resident macrophages release anti-inflammatory cytokines and are involved 
in non-immunological processes, such as remodeling (repair) of AT and lipid metabolism, helping to 
preserve normal adipocyte function [42]. 
During the development of obesity, dynamic changes in the number of ATMs and also of their phenotype 
occur in a way that mirrors the concept of T-cell activation [36, 43]. M1 or “classically activated” 
macrophages are produced upon exposure to T-helper 1 (Th1) type cytokines or inflammatory mediators 
such as lipopolysaccharide (LPS), express CD11c in addition to CD11b and F4/80 and are involved in 
inflammatory processes (such as combating infectious agents) [44]. Thereafter, they release inflammatory 
cytokines such as interleukin (IL)-6 or tumor necrosis factor (TNF)-α and generate reactive oxygen species. 
M2 or “alternatively activated” macrophages are produced upon exposure to T-helper 2 (Th2) cytokine 
such as IL4 or IL13, express phenotypically CD206, CD11b, F4/80 and CD301 markers and factors including 
IL10, arginase and play a role in immunosuppressive activities (namely as tissue repair) [45-47]. 
Polarization of macrophages in AT is thought to confer similar properties. As mentioned above, for 
example M2 macrophages predominantly make up the tissue-resident macrophages and support AT 
homeostasis, while M1 macrophages in obese AT likely promote inflammation leading to metabolic 
inflammation [48]. The secretion of inflammatory cytokines and chemokines by ATMs is under the control 
of two key intracellular inflammatory pathways, c-Jun N-terminal kinase (JNK) - activator protein (AP)-1 
and IB kinase (IKK) β - nuclear factor- B (NF-B), which are initiated by different mediators including 
oxidative and endoplasmic reticulum stresses, saturated fatty acids, and inflammatory cytokines but 
converge on the induction of overlapping inflammatory genes [49].  
As obesity develops with excess of energy storage, adipocytes will expand by increasing their size and/or 
increasing their number. Enlarged adipocytes become stressed and subsequently attract immune cells. 
Several changes in cellular immune processes have been reported. One may be increased infiltration of 
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macrophages in AT and an increase in the number of generally pro-inflammatory M1 macrophages. It is 
unclear what initially triggers M1 activation but nutritional signals and/or reduced angiogenesis and local 
adipose cell hypoxia from adipocyte hypertrophy have been pointed as possible culprits. This increased 
infiltration of macrophages in inflamed AT, mainly in vAT, contributes to exacerbation of inflammation 
[50]. In several murine models of diet-induced obesity, a switch in ATM polarization state from M2 to M1 
was demonstrated [51]. Newly recruited ATMs display a more pro-inflammatory profile than resident 
ATMs in lean mice [44] and resident macrophages express genes characteristic of M2 activation state. 
Nevertheless, ATM subsets show no restrict M1 or M2 polarization [52, 53].  
Increases in adipocyte diameter may also contribute to increased macrophage infiltration in the AT since 
hypertrophic adipocytes are prone to apoptotic and necrotic degeneration where adipocytes will be 
surrounded by macrophages, forming crown-like structures (CLS). The inflammatory response is amplified, 
since, for each dead adipocyte, several macrophages are recruited, perpetuating dysfunction in a vicious 
cycle [54]. Finally, changes in other AT immune cell populations such as an increase in the number of B 
cells and T CD8+ cells infiltration and a decrease in the number of regulatory T cells may also occur [55, 
56].  
All changes in AT inflammation including the increase in adipocyte size, increase in the number of 
infiltrating macrophages and CLS are associated with the increased inflammatory cytokines, chronic low 
grade-inflammation and comorbidities associated with obesity [57, 58]. Importantly, ATMs may signal AT 
stress and inflammatory status to other organs and could thereby contribute to the inter-organ cross-talk 
linking obesity to second organ dysfunction [59]. Evidence presented above suggests that macrophages 
have paramount importance in the genesis of obesity complications. 
 
Adipocyte dysfunction, inflammation and cardiometabolic risk 
It has been suggested that this low-grade inflammation is also a major player in the installation of the 
metabolic syndrome, a cluster of risk factors including central obesity, impaired glucose tolerance or 
diabetes, hypertension, and dyslipidemia with high plasmatic concentration of triglycerides and low 
concentrations of high density lipoprotein (HDL) cholesterol, all which can contribute to the increased risk 
in developing type 2 diabetes (T2D) and cardiovascular disease (CVD) [54, 60]. 
 Following the onset of obesity, the secretory status of adipocytes can be modified by the changes in the 
cellular composition of the tissue, including alterations in the number, phenotype and localization of 
immune, vascular and structural cells. Thus, via the secretion of pro-inflammatory adipokines and 
emigrating immune cells, including macrophages, “inflamed” AT may signal its functional status to other 
organs. In fact, adipokines may play specific roles not only in immune response (e.g. ILs, 
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adipsin/complement factor D, acylation-stimulating protein, serum amyloid A3) and inflammation (e.g. 
IL1β, IL6, IL8, IL10, C-reactive protein (CRP), MCP-1, osteopontin, progranulin, chemerin) but also in 
glucose metabolism (e.g. leptin, adiponectin, dipeptidyl peptidase (DPP)-4, fibroblast growth factor, 
resistin, vaspin), lipid metabolism (e.g. CD36), insulin sensitivity (e.g. leptin, adiponectin, chemerin), 
adipogenesis and bone morphogenesis (e.g. bone morphogenetic protein-7), regulation of appetite and 
satiety (e.g. leptin, vaspin), vascular tone (e.g. angiotensinogen), cell adhesion (e.g. plasminogen activator 
inhibitor (PAI)-1), vascular growth and function (e.g. vascular endothelial growth factor (VEGF)), 
atherosclerosis development (e.g. cathepsins, apelin) growth (e.g. insulin-like growth factor (IGF)-1, 
transforming growth factor beta (TGF)-β, fibronectin), among other biological processes. An adipokine 
pattern with low circulating adiponectin and high concentrations of chemerin, IL6, TNF-α, CRP, DPP-4 and 
others may reflect AT dysfunction [41, 61]. This diabetogenic, pro-inflammatory and atherogenic 
adipokine pattern may link adipocyte dysfunction to the metabolic syndrome.  
In addition to changes in adipokine secretion, impaired expandability of scAT, ectopic fat deposition and 
hypoxia may contribute to AT inflammation or dysfunction. The AT expandability hypothesis infers that, 
for some obese individuals, scAT may reach its maximal storage capacity, the excess of lipids then being 
reoriented, and thus excess visceral adiposity may be a marker of the relative inability of the scAT to 
expand through hyperplasia in face of a positive energy balance. Furthermore, as a hypertrophic AT 
cannot properly expand to store extra dietary lipids, there is, as result, a spillover of its lipid content 
leading to accumulation at undesired sites (heart, liver, skeletal muscle, pancreas) through a process 
called ectopic fat deposition [62, 63]. It has been therefore suggested that impaired subcutaneous 
vascularisation capacity may contribute to lower scAT expandability and metabolic diseases [23]. On the 
other hand, this enlargement of adipocyte size may result in a shift toward a predominance of pro-
inflammatory factors including leptin, IL6, IL8, MCP-1 [64], reduced levels of the insulin-sensitivity-related 
adipokine adiponectin and IL10 [64, 65], and have increased basal and catecholamine-stimulated lipolysis 
[66].  
Conversely, from 10 to 25% obese individuals are characterized by increased lipid deposition in the scAT 
depot and conserved AT functions, and these are considered metabolically healthy obese (MHO). In 
general, healthy obesity describes the absence of any metabolic disorder including T2D, dyslipidemia or 
hypertension in an obese individual (BMI >30 kg/m2) [67, 68], thus suggesting that obesity is not 
equivalent to metabolic dysfunction. Recent studies revealed that independent of body mass index (BMI), 
age and sex, increased visceral fat accumulation, inflammation in vAT and insulin resistance resulting from 
AT dysfunction may contribute to unhealthy obesity [69]. However, the causal factors leading to 
transitions between the MHO to the metabolically abnormal obese (MAO) phenotype are poorly 
understood. For the reasons described above, the MHO phenotype has received increasing interest in 
recent years, and indeed, stratification of obesity phenotypes could help improve therapeutic decision-
making. 
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An often underappreciated finding is that AT function and deposition differ with sex. Indeed, the marked 
sex dimorphism in body fat patterning in humans indirectly suggests that sex hormones play a key role in 
regional fat accumulation. Women have an overall higher total body fat content when compared to men. 
Importantly, women differ with respect to distribution of AT. Men tend to accrue more vAT, leading to 
classic android body shape, which has been highly correlated with CVD risk, whereas premenopausal 
women have a greater proportion of body fat accumulated in subcutaneous (gluteofemoral) location, a 
feature associated with protection from negative consequences associated with obesity, although in both 
genders the subcutaneous is the main site of accumulation [70, 71]. In women, estrogens may protect 
against increased body adiposity through their effects in appetite suppression (enhancing potential 
anorexigenic signals, such as cholecystokinin, apolipoprotein A-IV, leptin, brain derived neurotrophic 
factor, and by decreasing the potency of orexigenic signals such as melanin-concentrating hormone and 
ghrelin) [72-74] and increase energy expenditure [75, 76]. Interestingly, as a woman reaches menopause, 
body fat is redistributed, depot differences in adipocyte size tend to be attenuated, since the size of 
omental cells seem to be specially increased. Women tend to acquire a body fat accumulation pattern 
similar to men [71, 77], and this redistribution may be linked to the age-related decrease in estrogens 
levels [78], with the shift to favor the visceral depot being accompanied by a parallel increase in metabolic 
risk reminiscent to that seen in men. Premenopausal women are less prone to develop cardiovascular and 
metabolic disease than age-matched men. It is generally accepted that a great part of the increase in 
cardiometabolic risk after menopause is accounted for by the decline in ovarian production of estrogens 
[79], illustrating estrogens’ protective effects on the cardiovascular system [80, 81], whereas men and 
postmenopausal women, whose estrogen levels are low, have increased metabolic risk translated into 
higher likelihood to develop CVD [82].  
In parallel, epidemiological studies show that premenopausal women are less likely to develop 
inflammation compared to age-matched men, suggesting a protective effect of estrogens also against 
inflammation [83, 84]. The higher propensity for developing abdominal adiposity of postmenopausal 
women may help explain their increased systemic levels of inflammatory cytokines, also indicating that 
estrogens can modulate both body adiposity and systemic inflammation [85].  
 
Estrogen metabolism and signaling  
At present, it is well recognized that the impact of estrogens in humans is wider than their effect on 
reproduction, due to their participation in the regulation of a diversity of functions including the 
differentiation of several tissues, the modulation of inflammation and metabolic processes.  
Estrogens are synthesized by aromatase, a cytochrome P450 enzyme located in the endoplasmic reticulum 
of estrogen producing cells which catalyzes the aromatization of testosterone and androstenedione [86], 
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to 17β-estradiol (E2), the most active estrogen, and estrone, respectively [87]. In humans, estrogens are 
generated in several tissues including ovaries, testis, placenta, fetal but not adult liver, bone chondrocytes 
and osteoblasts, vascular smooth muscle cells, skin, skeletal muscle, several brain regions, and the AT [86, 
88, 89]. The gonads and the adrenals express all the necessary enzymes to synthesize estrogens from 
cholesterol whereas other tissues, such as the bone or the AT, depend on precursor supply from those 
organs through the blood [90]. In peripheral tissues, 17β-hydroxysteroid dehydrogenase (17β-HSD) 
converts the weaker hormones androstenedione and estrone to stronger ones, testosterone and E2, 
respectively. 
In premenopausal women, most estrogens are produced in the ovaries, released to the circulation in large 
amounts and exert their effects in many target tissues through endocrine signaling. After menopause, 
when estrogen production from the ovaries falls, circulating levels of estrogens decrease dramatically [91] 
and estrogen synthesis is mainly assured by peripheral sources, primarily by the AT [92]. Estrogens are 
also produced during the entire male life cycle, having an action pattern similar to that observed in 
postmenopausal women in which endocrine actions lose relevance to paracrine, autocrine, and intracrine 
actions in the tissues or in the cells that produce them [86]. Thus, regardless of low circulating levels, local 
estrogen concentrations may be high, reflecting on their biological actions [93]. 
Estrogen distribution occurs after estrogen sulfotransferase action which constitutes a critical mediator of 
hormone effects [71]. Although estrogen sulfates are biologically inactive, they have prolonged half-life in 
the circulation, acting as a reservoir for regeneration of active estrogens by steroid sulfatase-mediated 
desulfation [94]. 
Two basic estrogen receptors (ERs) are important in estrogen signaling: the ERα and ERβ. Both ERs are 
widely distributed throughout the body, displaying distinct but overlapping expression patterns in a 
variety of tissues [95]. ERs function as ligand-related transcription factors, regulating numerous important 
physiological process such as the development, reproduction, behavior, metabolism, and regulation of the 
cardiovascular system [96].  
Estrogen signaling mediated through both ERs by classical genomic and non-genomic mechanisms, 
although largely resulting in activation of distinct targets may also have coinciding activities (Figure 1). 
Classical genomic signaling through the ERs occurs within hours of ligand binding, activating or repressing 
target genes. ERs are located as monomers in the cytoplasm in protein complexes involving chaperone 
heat-shock proteins and estrogen binding promotes their dissociation from this complex and ER 
dimerization (homodimers of ERα or ERβ or heterodimers of ERα-ERβ). ER dimers bind directly to estrogen 
response elements of target gene promoters, or indirectly through interaction with other DNA-bound 
transcription factors like AP-1, NF-B, and specificity factor (SP)-1 [97, 98]. 
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ERs also regulate gene expression in a ligand independent manner by interacting with other nuclear 
hormone receptors, such as peroxisome proliferator-activated receptors (PPARs) [99]. After DNA binding, 
ER dimers regulate gene expression interacting with cofactors (coactivators or cosuppressors) [71, 100, 
101]. The nature and concentration of the ligand, the type of dimer formed, the kind of DNA interactions 
(direct or indirect), and the presence of distinct cofactors according to cell type or condition, all constitute 
sources of variation of ER-activated transcriptional activity. Furthermore, there appears to be ERα 
dominance since when both receptors are present this receptor seems to be the driver of the response for 
either genomic or non-genomic responses, while ERβ when in the presence of ERα tends to antagonize its 
responses [102]. While most of the reproductive effects of estrogens are mediated through classical ER 
signaling, metabolic effects seem to be largely mediated through non-nuclear ERs and involves activation 
of ERs located at the membrane or at extranuclear sites within seconds or minutes [71, 77]. Mechanisms 
of non-genomic actions are not completely known but second messenger activation after estrogen binding 
results in changes in Ca2+, K+, cAMP, and nitric oxide levels, action of G protein-mediated events and 
stimulation of different types of kinases such as extracellular signal-regulated kinases (Ras/Raf/MEK/ERK), 
phosphoinositide 3-kinases (PI3K), p38 mitogen-activated protein kinase (MAPK), and JNK [103, 104]. 
MEK/ERK pathway activation also regulates gene expression through activation of transcriptional factors 
such as cAMP-related element binding (CREB) protein or nuclear factor of activated T-cells [105]. With 
much relevance to the inflammation modulatory properties of estrogens is their capacity to influence NF-
B, inhibiting directly or indirectly part of its negative effects [101]. 
G protein-coupled receptor 30, now known as G protein-coupled ER (GPER), located on the plasma 
membrane [106] or with an intracellular localization [107] is also involved in rapid non-genomic estrogen 
signaling involving release of intracellular Ca2+ and activation of calcium-calmodulin-dependent kinases, 
PI3K and MAPKs [100]. Estrogen-related receptors (ERRs), a family of orphan receptors closely related to 
ERs, includes three members, ERRα, ERRβ, and ERRγ, and are expressed in muscle, heart, bone, and AT 
[108]. These nuclear receptors are not stimulated by estrogens or estrogen-like molecules, being 
constitutively active in the absence of ligand [109]. However, ERRs can interfere with estrogen signaling, 
recognizing the same DNA-binding elements as ERs and sharing common target genes [108]. ER and ERR 
are coexpressed in many tissues and ERRs play important functions in adaptative energy metabolism 
[109]. 
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Figure 1. Schematic illustration of how genomic and non-genomic actions of ERs on target gene promoters 
may converge. Estrogen signaling occurs through both genomic and non-genomic mechanisms. In 
classical, genomic, estrogen signaling ERs act as ligand-activated transcription factors, activating or 
repressing target genes within hours of ligand binding. ERs are located as monomers in the cytoplasm in 
protein complexes involving heat-shock proteins and estrogen binding promotes their dissociation from 
this complex and ER dimerization. ER dimers bind directly to estrogen response elements of target gene 
promoters, or indirectly through interaction with other DNA-bound transcription factors. ERs also regulate 
gene expression in a ligand independent manner being activated downstream to growth factors binding to 
growth factor receptors, through the action of intracellular kinases or through the formation of 
heterodimers with different nuclear receptors (not shown). Genomic actions are modulated by cell-
specific interaction with cofactors (coactivators or cosuppressors). Metabolic effects of estrogens seem to 
be largely mediated through non-nuclear ERs, either by interference with gene expression or by exerting 
non-genomic actions. This involves activation of ERs and G-protein-coupled ER located at the membrane 
or at extranuclear sites within seconds or minutes resulting in changes in Ca2+, K+, cAMP, and nitric oxide 
levels, activation of G protein-mediated events, and stimulation of different types of kinases such as 
extracellular-regulated kinases, phosphoinositide 3-kinases, mitogen-activated protein kinase, and c-Jun 
N-terminal kinases. E: estrogen; ER: estrogen receptor; ERE: estrogen-response element; ERK: extracellular 
signal-regulated kinase; GFR: growth factor receptor; GPER: G protein-coupled estrogen receptor; HSP: 
heat-shock protein; JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kinase; NO: nitric 
oxide; PI3K: phosphoinositide-3 kinase; TF: transcription factor. Adapted from Monteiro et al. [110]  
 
 CHAPTER I 
 
 
- 18 - 
Adipose tissue and macrophages as targets of estrogens’ actions 
The influence of hormones on AT distribution appears to be related both to AT-specific expression of 
steroid hormone receptors and to local tissue steroid hormone metabolism. AT is an important site for 
estrogen biosynthesis and storage. Adipocytes from different depots differ in their capacity to produce 
estrogens, as aromatase expression declines from gluteofemoral, to abdominal scAT, to vAT [111]. 
Moreover, estrogens are secreted from AT in proportion to total fat mass [112] and are thought to signal 
the size of body energy stores and influence physiological processes through endocrine actions while also 
exerting important local effects through paracrine and autocrine actions.  
Estrogens can directly inhibit AT deposition by decreasing lipogenesis. This effect results mainly from 
decreasing activity of AT lipoprotein lipase (LPL), an enzyme that regulates lipid uptake by adipocytes. 
Ovariectomy increases LPL and lipid deposition in adipocytes and administration of physiological doses of 
E2 reverses this increase [113]. On the other hand, E2 can indirectly affect lipolysis by inducing the lipolytic 
enzyme hormone-sensitive lipase [114] or by increasing the lipolytic effects of adrenaline [115]. Moreover, 
fatty acid oxidation can also be increased, which might contribute to the decrease in AT mass induced by 
E2. However, contrary to its anti-lipogenic and lipolytic effect, estrogens favor the effect of α2a-adrenergic 
receptors in human scAT and decrease lipolysis. This effect could in part account for the increased 
deposition of scAT in women compared to men [116]. 
ERα and ERβ are expressed in both scAT and vAT in humans and rodents, denoting that in AT estrogen 
signaling may occur through either of these ERs [117]. ERα is particularly relevant when considering the 
metabolic actions of estrogens since diminished ERα activity is associated with obesity in women and men. 
Furthermore, impaired ERα action is a contributing factor in the pathobiology of the metabolic syndrome 
[118]. Additionally, human inactivating mutations of ERα recapitulate aspects of the metabolic syndrome 
[119]. Moreover, global deletion of the ERα gene in mice results in increased adiposity in both males and 
females, with near doubling of the intra-abdominal AT when compared to age-matched wild type mice 
[120, 121]. Nevertheless, mice with a deletion in ERβ do not have increased adiposity or metabolic 
derangements. Several studies have shown associations between ERα polymorphisms and increased AT 
accumulation particularly in the visceral compartment [122]. Moreover, both ERα and ERβ interfere with 
AT distribution, inflammation, fibrosis and glucose homeostasis. In 2013, Davis et al. [123] in a mouse 
model with ERα inactivation, especially in adipocytes, showed an increase in AT fibrosis and inflammation 
which was more marked in males, revealing that the protective effects of estrogens on AT are dependent 
upon adipocyte ERα-mediated signaling.  
Furthermore, dos Santos et al. [124] advocates that E2 can also act through membrane ER in adipocytes, to 
induce rapid effects through activation of MAPK, AP-1 and CREB protein. ERs are also expressed in 
preadipocytes [125] whereby estrogens can potentially regulate preadipocyte development and adipocyte 
differentiation. However, AT is much more than adipocytes. In fact, ERα and ERβ are also expressed in 
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other cell types found in AT, namely vascular endothelium, vascular smooth muscle and immune cells 
[121]. Thus, the effect of estrogens on AT must be viewed in light of a concerted action in all its different 
cell types. 
The infiltration of AT by macrophages constitutes an important point of possible regulation of both 
metabolic and inflammatory processes by estrogens. ERα and ERβ are present in monocytes and 
macrophages, and estrogens activate these cells [126]. With exception of monocytes, peripheral blood 
mononuclear cells of postmenopausal women have similar ER expression patterns compared with those of 
premenopausal women. ERα is expressed in higher amounts in monocytes compared to ERβ from 
postmenopausal women and men, which may result in altered estrogen responsiveness compared with 
monocytes of premenopausal women [127]. 
Macrophage differentiation strongly depends upon the local microenvironment. In activated 
macrophages, estrogens effects are primarily repressive, by inhibiting the expression of cytokines or 
modulating other inflammatory mediators by ER-dependent and/or non-genomic pathways in response to 
inflammatory signals [128, 129]. However, the majority of studies have only addressed the effect of 
estrogens on M1 cells and less is known about the effect on M2 macrophages. The roles of estrogens in 
macrophage-related inflammation are clearly complex. In mice, estrogens inhibit LPS-induced mouse 
homologue of MCP-1 in peritoneal macrophages as well as IL6, IL1 and TNF-α in splenic macrophages. 
Evidence also points to a role for estrogens in regulating monocyte migration behavior [130, 131]. 
From the evidence presented above, suppression of inflammatory responses represents a promising 
strategy to combat obesity and associated disorders. Recent studies establish the mechanistic potential 
for estrogens to affect the inflammatory process. ERα is the predominant receptor in macrophages and its 
expression is up-regulated by estrogens (in macrophages but not in monocytes), whereas ERβ is 
predominantly expressed in monocytes and is unaltered by estrogens in either cell type [132]. 
 
Xenoestrogens  
Apart from endogenously-produced estrogens, a wide array of xenobiotic substances with potential to 
interfere with estrogens synthesis, storage/release, metabolism, transport, elimination or receptor 
binding [133, 134] occur in nature. These compounds are either natural or man-made chemicals and are 
collectively termed xenoestrogens (XEs) or estrogen disruptors. Molecules like phytoestrogens, but also 
chemicals produced by industrial processes and released into the environment, namely, the plasticizers 
phthalates or bisphenol A (BPA), organotins, pesticides, dioxins, polychlorinated biphenyls (PCB), 
brominated flame retardants (BFR), or alkylphenols  belong to this group [135]. These XEs have in 
common phenolic rings and other hydrophobic components (Figure 2), a characteristic they share with 
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steroid hormones and related nuclear receptor-activating compounds. They also exhibit potent lipophilic 
properties and long half-lives [136]. Phytoestrogens are XEs found naturally in certain plants, including 
foods like whole grains, leafy greens, beans, and garlic, and can mimic the action of estrogen, showing 
some beneficial effect on bone mineral density, insulin resistance, and CVD risk factors in women after 
menopause [137, 138]. Another class of XEs belongs to the group of heavy metals (i.e., cadmium, mercury, 
and arsenic). These metals may be involved in occupational or residential exposure [139, 140]. 
 
 
Figure 2. Chemical structures of aldrin, bisphenol A (BPA), di-n-butyl phthalate (DBP), 
dichlorodiphenyldicloroethylene (DDE), di-ethyl-2-hexyle phthalate (DEHP), hexachlorobenzene (HCB), 
hexachlorocyclohexane (HCH) and 17β-estradiol (E2).  
 
Some synthetic XEs are persistent in the environment and accumulate in the food chain and in human 
biological matrices [141]. Epidemiological studies have shown that exposure to XEs is near ubiquitous 
among humans, and commonly occurs by ingestion of contaminated food or through occupational 
contact. Environmental estrogens produce non-genomic effects similar, but not identical, to those elicited 
by E2, but there is a paucity of data on their ability to mediate non-genomic effects at low concentrations 
[142-144]. Due to their ubiquity, it is expected that an individual will be contaminated with more than one 
compound, sometimes from different classes, enabling possible additive or synergistic effects [145].  
Such estrogen mimetics were noted for their effect on wildlife in the 1960´s when Rachel Carson drew 
attention to the endocrine-disrupting effects of some pesticides, notably the organochlorine pesticide 
dichlorodiphenyltrichloroethane (DDT) [146]. Using cross-sectional data from the 1999–2002 US National 
Health and Examination Survey, Duk-Hee Lee et al. [147] reported a prevalence of a cluster of CVD risk 
factors that relates to background exposure to a mixture of persistent organic pollutants (POPs), some 
with xenoestrogenic activity. 
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Given the lipophilic nature of these contaminants, the AT is a central part of their kinetics on the organism 
of humans and other animals. Despite the presence of a large number of AT cell types, XE storage in AT is 
believed to be primarily in the adipocytes [148]; AT storage of a variety of hydrophobic xenobiotic 
chemicals can be viewed as protective, limiting their systemic toxicity by preventing high blood levels of 
these XEs and subsequent high exposure of other sensitive organs and tissues, such as the brain, liver and 
pancreas. However, there are few studies on XE distribution across AT depots and plasma, on the 
relationship between plasma and tissue levels, or on their different prevalence in different population 
subgroups.   
Furthermore, AT has important endocrine and metabolic functions and could itself be a privileged target 
of these pollutants (Figure 3) [149-151]. Ample research establishes AT storage of XEs as a central factor in 
toxicity [149, 152], but significant knowledge gaps remain with regard to mechanisms of action, XE 
distribution and dynamics in the body, and the molecular pathways disrupted by or involved in XE toxicity.  
 
 
Figure 3. Overview of the changes that occur during adipose tissue growth. Adapted from Myre et al. 
[151]. Adipose tissue (AT) is classically viewed as the main reservoir of energy mobilized from the body. It 
is composed of a great diversity of cells, such as adipocytes, preadipocytes, vascular cells, neurons, 
fibroblasts, and immune cells, as resident M2 macrophages. Obesity evolution is characterized by AT 
growth through adipocyte hypertrophy/hyperplasia, but also by the accumulation of M1 macrophages in 
AT depots. These macrophages infiltrating the AT are arranged around dead adipocytes, forming 
characteristic crown-like structures. At the same time, AT store a variety of lipophilic compounds, 
including xenoestrogens (XEs). The accumulation of XEs within AT is believed to decrease their availability 
to other cells and tissues, thereby limiting their systemic toxicity. However, XEs released from their 
storage site in the AT constitute a source of low-level internal exposure, apart from the possibility of 
exerting local toxicity. 
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AIMS 
 
 
The general aim of this investigation was to assess the effects of endogenous estrogens or xenobiotic 
molecules with ability to interfere with estrogen signalling systems on the modulation of the low grade 
systemic inflammatory state that accompanies obesity and the related metabolic abnormalities. The 
specific aims, related to our different approaches, were the following:  
Chapter II 
- To determine XEs levels in human samples of blood and AT from subcutaneous and visceral 
locations of obese women and understanding differences according to menopausal state; 
- To search for a putative relationship between plasma and AT XEs with cardiometabolic risk and 
the possible use of XEs as markers of dysmetabolic obesity; 
Chapter III 
- To characterize  the response of macrophages in different polarization states to estrogens; 
Chapter IV 
-  To determine effect of or XEs in estrogen signaling and behaviour of human macrophages. 
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In their recent paper Gauthier et al. (1) interestingly demonstrate the relationship of persistent
organic pollutants (POPs) with the variation in metabolic risk observed among obese
individuals showing that the metabolically healthy but obese (MHO) phenotype is associated
with lower plasma levels of POPs as compared with metabolically abnormal obese (MAO)
subjects.
In fact, many epidemiological studies have used circulating concentrations of POPs as a
marker of body burden of the compounds. However, the adipose tissue (AT) is the main
reservoir of POPs and, although circulating POP concentrations have been reported to be
correlated with those in AT, plasma POP levels are more transient and measurement of AT
POP levels are undoubtedly a better way to estimate whole body POP accumulation (2).
Usually POP accumulation in AT can be regarded as protective by preventing the systemic
effects of these compounds. In addition to its function as POP reservoir, the AT can also be a
target of their disruptive effects, with putative local and systemic consequences (3). Recently
our group revealed that, POP levels either in subcutaneous and visceral AT (vAT) were
higher in subjects with evidence of metabolic abnormalities. This pattern was especially
evident for vAT, supported by higher vAT POP levels in patients with increased aggregation of
metabolic syndrome components and higher 10-year cardiovascular risk based on the
Framingham score (4).
We believe that the higher accumulation of POPs observed in vAT is of paramount
importance since this highly metabolically active tissue is held as the main impeller of
metabolic dysfunction progression. Moreover, longer exposure times, such as those expected
to occur for example in postmenopausal women, may reflect in higher POP concentrations in
AT imposing on the likelihood of local toxicity. Further, Bluher et al. (5) advance that
inflammation is one of the main factors discriminating 'healthy' from 'unhealthy' obese
individuals, and vAT inflammation largely contributes to the inflammatory state associated
with obesity. Therefore, higher POP accumulation on vAT of obese individuals may induce or
exacerbate local inflammation contributing to metabolic deterioration associated with obesity
and constituting a possible factor discriminating the two subpopulations.
Another interesting point of discussion is that vAT is more susceptible to lipolysis probably
resulting in increased POP release. As metabolic dysfunction is mainly associated with
increased vAT, one can speculate if POPs, which we have demonstrated to be accumulated
in higher amounts in this AT depot, are, on the one hand hampering its normal function and,
on the other, promoting a consequent POP release into the bloodstream. Our hypothesis is
corroborated by the increase of plasma POP levels in MAO and is consistent with the notion
that once POPs return to circulation they become free to act in distant organs possibly
contributing to cardiometabolic complications.
This implies the broader effect of environmental POPs, in which the impairment of AT normal
function seems to play an important role, reinforcing the need for a paradigm shift of the view
of POPs as mere obesogen compounds and introducing them as possible markers of
dysmetabolic obesity.
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ABSTRACT 
 
Purpose: Evidence is being gathered on the effect of estrogens on the immune system. However, little is known about their effects on 
the differential expression of estrogen receptor subtypes or on the putatively distinct effects on macrophages in different activation 
states. This study was carried out to evaluate if estrogen treatment of classically (M1)- or alternatively (M2)- differentiated 
macrophages could affect their behavior.  
Methods: Human peripheral blood monocyte-derived macrophages after M1 or M2 activation were treated with 17β-estradiol (E2) 
alone or in combination with selective estrogen receptor (ER) α or ERβ antagonists. Macrophage cytokine release, migratory capability 
and estrogen-associated signaling pathways were evaluated. 
Results: ERα and ERβ mRNA were differently expressed among different stages of macrophage activation. E2 significantly induced 
M1 release of interleukin (IL) 10 and IL6 and decreased IL10, IL6, TNFα and IL1β release by M2 macrophages. Moreover, E2 also 
stimulated M2 migration. Most E2 effects were shown to be mediated by either ERα or ERβ and/or by orchestrating NF-B, AP1, JNK 
and ERK signaling pathways.  
Conclusions: We provide evidence that both pro- and anti-inflammatory programs can co-exist within the same macrophage and may 
be programmed by E2 into either direction depending on the surrounding environment, which may represent an interesting target to 
modulate inflammation. 
Keywords: estrogen, estrogen receptors, M1 macrophages, M2 macrophages, inflammation  
 
 
INTRODUCTION 
 
Knowledge on the pleiotropic functions regulated by 
estrogens in different tissues and organs has evolved rapidly 
during the past decade. Given the widespread role of estrogens 
in human physiology, it is not surprising that estrogens are also 
implicated in the development or progression of several 
common pathological conditions, which include (but are not 
limited to) asthma, atherosclerosis, osteoporosis, insulin 
resistance, neurodegenerative diseases, as well as obesity [1-6]. 
Among other physiological roles, there is growing evidence that 
estrogens influence the immune system and the processes 
associated with inflammation [7, 8]. 
The biological actions of estrogens are largely mediated by 
two distinct estrogen receptor (ER) isoforms, namely ERα and 
ERβ, that are distributed in different cell types including 
monocytes/macrophages [9, 10]. ERs are members of the 
nuclear receptor family and act as ligand-activated transcription 
factors to regulate the expression of target genes, which control 
both specific and overlapping physiological effects of estrogens 
[11]. ERs mediate not only genomic but also a series of non-
genomic actions of estrogens.  
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Moreover, a number of different signaling pathways have been 
found to be activated by estrogens in different cell types, 
namely ERα-mediated extracellular signal regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK) and 
phosphatidyl-inositol-3-kinase/AKT (PI3K/AKT) pathways, as 
well as ERβ-mediated p38/MAPK. Furthermore, some 
transcriptional activity can be regulated by protein-protein 
interaction of ER with other specific transcription factors, such 
as activator protein (AP) 1 and nuclear factor-B (NF-B) [12, 
13]. 
Newly formed monocytes leave the unique environment of 
the bone marrow and enter the blood, where they are exposed to 
a plethora of agents, which are capable of impacting on their 
functional and phenotypic characteristics. Under stimulation, 
these cells selectively home to different tissues, undergo 
differentiation into macrophages, and upon entry, migrate to the 
inflammatory focus, a central and rate-limiting step in 
inflammation [14]. Tissue macrophages experience a hierarchy 
of activation or polarization states that ensure baseline tissue 
homeostasis and prevent constant inflammation which, in case 
of occurrence, underlies the pathophysiology of numerous 
chronic and metabolic diseases [15]. 
Functional heterogeneity and plasticity are hallmarks of the 
monocyte/macrophage lineage. In response to various signals, 
macrophages may undergo classical activation (M1, stimulated 
by lipopolysaccharide, LPS) or alternative activation (M2, 
stimulated by interleukin (IL) 4), states that mirror the Th1-Th2 
polarization of T lymphocytes [16]. In addition, pathological 
states are frequently associated with dynamic changes in 
macrophage activation, with classically-activated M1 cells 
implicated in initiating and sustaining inflammation and M2 in 
resolving  or containing chronic inflammation [17]. 
Monocyte-derived macrophages (MDM) are commonly 
accepted as a good surrogate of macrophages infiltrating tissues. 
Distinct phenotypes are currently obtained upon monocyte 
exposure to bacterial agents or cytokine/chemokine cocktails 
allowing M1 or M2 activation [18]. Nevertheless, the potential 
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influence of estrogens on these divergent cell populations is 
unclear.  
Macrophage function is profoundly affected by the 
environment to which they are exposed, including not only 
cytokines and chemokines but also steroid hormones.  
Although the prominent role of different types of nuclear 
receptors in the orchestration of macrophage polarization in 
several inflammatory diseases is well established, and previous 
studies have shown that estrogens mediate effects on monocyte 
and macrophage immune function [19, 20], the exact 
contribution of estrogen-regulated pathways to macrophage 
polarization remains unclear. In fact, the connection between 
macrophage polarization and estrogens is just beginning to be 
described and seems to be relevant in vivo under physiological 
and pathological conditions [21]. Furthermore, very little is 
known about whether the expression of the ERs varies with 
macrophage polarization stage.  
The current study was devised in order to further clarify the 
immunomodulatory potential and underlying mechanisms of 
estrogen action in human MDM according to activation state. 
We further hypothesized that estrogen treatment of macrophage 
after differentiation with LPS or IL4 could modify their profile 
of cytokine release. Finally, we sought to determine if the 
effects of estrogen treatment are mediated by estrogen 
associated signaling pathways. 
 
 
MATERIALS AND METHODS 
 
Peripheral blood-derived macrophages 
 
Leukocyte-rich buffy coats were obtained from blood donor 
healthy female volunteers between the ages of 50 and 62 years 
recruited from the Department of Immunohemotherapy, São 
João Hospital, Porto, Portugal, following a protocol approved 
by the Ethical Committee for Health of Hospital São João and 
after written an informed consent. 
Human peripheral blood mononuclear cells (PBMCs) were 
isolated by density-gradient centrifugation using 
Histopaque®1077 (Sigma Aldrich, Sintra, Portugal), according 
to the manufacturer’s protocol. Briefly, blood was diluted with 
one volume of phosphate-buffered saline. This mixture (30 mL) 
was layered over 10 mL of Histopaque® and centrifuged at 800 
× g for 30 min at room temperature. After three washes, PBMCs 
were resuspended in RPMI-1640 phenol-red free medium 
(Sigma Aldrich, Sintra, Portugal) and counted. PBMCs obtained 
from six different donors were pooled to reduce variability. 
Furthermore, all women were postmenopausal as classified after 
clinical endocrinology evaluation according to American 
Association of Clinical Endocrinologists Medical Guidelines, 
having more than one year without menses [22], in order to 
avoid a possible preconditioning effect of different levels of 
circulating estrogens from premenopausal women. 
Differentiation of monocytes into macrophages occurs 
spontaneously by adhesion of cells to the plastic culture dishes 
[9] (21 cm2; Ø 60 mm; Orange Scientific, Belgium). Cells were 
maintained in the presence of RPMI-1640 medium with 10% 
fetal bovine serum (FBS; Gibco, Paisley, UK), 2 mM L-
glutamine, 100 U/mL penicillin and 100 U/mL streptomycin 
(Sigma Aldrich, Sintra, Portugal) for 7 days at 37oC in a 
humidified atmosphere with 5% CO2. For macrophage 
differentiation and alternative activation (M2), freshly-plated 
monocytes were stimulated with human recombinant IL4 (15 
ng/mL; Sigma Aldrich, Sintra, Portugal) added at the beginning 
of differentiation and for 7 days. The classical activation of 
macrophages was achieved through the incubation of adherent 
cells (macrophages) on day 7 in culture medium, with 100 
ng/mL LPS (classical activation stimulus, M1; Escherichia coli 
0111:B4, Sigma Aldrich, Sintra, Portugal) at 37°C for 24 h. 
Control macrophages (M) were obtained through a similar 
procedure (7 days of culture)  but received no stimulation. 
Immunofluorescence analyses of culture cells after 
differentiation showed that more than 95% were positive for 
CD68, a marker for differentiated macrophages. Briefly, 
macrophages were differentiated on 8-well Falcon® slides, 
washed with PBS, fixed in 4% -formaldehyde and 
permeabilized with 1% triton X-100. M cells were stained with 
rabbit-anti-CD68 (200 μg/mL). M1 cells were stained with 
rabbit-anti-CD68 (200 μg/mL) and mouse-anti-CD11c (200 
μg/mL) and M2 cells were stained with rabbit-anti-CD68 (200 
μg/mL) and goat-anti-CD206 (200 μg/mL) followed by 
incubation with FITC and Texas red secondary antibodies [23, 
24]. Cell nuclei were counterstained with 4′,6-diamidine-2′-
phenylindole dihydrochloride (DAPI; Roche, Amadora, 
Portugal). Fluorescence images were acquired using a 
fluorescence microscope (Nikon Eclipse 50i®, Melville, USA) 
at a magnification of x200 and their analysis performed with 
ImageJ software® (National Institute of Health, Bethesda, 
USA). Negative controls were carried out by omission of the 
primary antibody. All antibodies were purchased to Santa Cruz 
Biotechnology, Heidelberg, Germany. The cells were 
subsequently washed and cultured in serum-free medium during 
24 h and were then treated with 17β-estradiol (E2, 10
-11 M; 
Sigma Aldrich, Sintra, Portugal) in serum-free medium 
supplemented with 0.05% bovine serum albumin (BSA, Sigma 
Aldrich, Sintra, Portugal), for 24 h in all experiments. To assess 
the ER-dependence of the E2 effect, cells were exposed to the 
selective ERα antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-5-
[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride 
(MPP, 10-6 M; Sigma Aldrich, Sintra, Portugal) or the selective 
ERβ antagonist  4-(2-phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl)phenol 
(PHTPP, 10-6 M; Santa Cruz Biotechnology, Heidelberg, 
Germany) added at the same time as E2. After 24 h incubation, 
supernatants were collected and stored at -80oC for the 
determination of cytokine levels.  
A stock solution of each compound used for treatments was 
prepared in dimethyl sulfoxide (DMSO; Merck, Darmstadt, 
Germany) and kept at -20ºC. Appropriate dilutions of each 
compound were freshly prepared just prior to every assay. The 
effect of the vehicle (at a final concentration of 0.1%) was 
evaluated in all experiments.  
 
 
RNA isolation, cDNA synthesis and qRT-PCR 
 
Total RNA was isolated from the cells using STAT-60 
reagent (AMS Biotechnology, Abingdon, UK) followed by 
chloroform extraction and isopropanol precipitation. RNA 
extracts were treated with DNase (RQ1 RNase-free DNase, 
Promega, Carnaxide, Portugal) to avoid contamination with 
genomic DNA and its concentration was assessed 
spectrophotometrically with a NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
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USA). For qRT-PCR analysis, total RNA (1 µg) was reversely-
transcribed using the NZY First Strand cDNA synthesis kit 
(NZYTech, Lisbon, Portugal) in accordance to the 
manufacturer’s protocol. 
qPCR was carried out using a LightCycler 96 (Roche, 
Amadora, Portugal). All cDNA samples were analysed in 
duplicate by qRT-PCRs conducted with SYBR green qPCR mix 
(FastStart Essential DNA Green Master; Roche, Amadora, 
Portugal). Cycling conditions were as follows: denaturation 
(95oC for 5 min), amplification and quantification [95ºC for 10 
s, annealing temperature (AT) for 5 s, and 72oC for 10 s, with a 
single fluorescence measurement at the end of the cycle 
repeated 45 times, a melting curve program [(AT+10)oC for 15 s 
and 95oC with a heating rate of 0.1oC/s and continuous 
fluorescence measurement], and a cooling step to 37oC. Human-
specific primers (Table 1), purchased from Sigma Aldrich 
(Sintra, Portugal) were used for qRT-PCR analysis. 
Data were analyzed using LightCycler analysis software 
(version 1.0). Gene expression was calculated using the 2-ΔCT 
method [25], where the CT was the threshold concentration, and 
normalized against the geometric mean expression levels of the 
endogenous control gene hypoxanthine-guanine-
phosphoribosyltransferase (HPRT). 
 
 
Table 1 
Primers used for quantitative real-time PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hprt, hypoxanthine phosphoribosyltransferase; COX2, cyclooxygenase (COX) 2; CREB1, cAMP response element-binding protein 1; ERα, estrogen receptor α; ERβ, 
estrogen receptor β; ERK2, extracellular signal-regulated kinase 2; IkBα, inhibitor B α; JNK1, c-Jun N-terminal kinase 1; NF-B, nuclear factor-B, p50 subunit; 
RelA, nuclear factor-B, p65 subunit 
 
 
Cytokine ELISA assay 
 
IL1β, IL6, IL10, and TNFα concentrations in cell media were 
measured using, respectively, LEGEND MAXTM Human IL1β, 
IL6, IL10, and TNFα ELISA kits (BioLegend Inc., San Diego, 
CA, USA), according to the manufacturer’s instructions.  
 
Migration assay 
 
Human MDM migration was assayed using the Chemicon 
QCM Migration kit (96-well, 5-μm pore size; Merck Millipore, 
Madrid, Spain) according to the manufacturer’s directions. 
Freshly isolated human peripheral blood MDM, and after 
polarization as described previously, were plated at a density of 
2x104 cells/well in serum-free culture medium supplemented 
with 0.05% BSA added to the upper chamber in the presence of 
E2, MPP, PHTPP or vehicle. Culture medium with 10% FBS 
(constituting the chemotactic stimulus of the assay) was added 
to the lower chamber and cells were incubated at 37ºC and 5% 
CO2 for 24 h. After incubation, 75 µL of suspension containing 
cells that migrated was transferred from the migration feeder 
tray to the well of a new 96-well plate, while the migrated cells 
that were still attached to the bottom side of the migration 
chamber filter were dislodged by incubating in Cell Detachment 
Solution (Chemicon) for 30 min (37oC in 5% CO2). Seventy 
five µL of dislodged cell suspension were mixed with the cells 
that were previously collected from the migration feeder tray 
and incubated for 15 min with 50 mL of Lysis Buffer/Dye 
Solution (Chemicon) after which fluorescence was read using 
the 480/520 nm filter set on a fluorometric plate reader. 
Exposure of macrophages to culture medium with 10% FBS 
consistently induced migration in control wells of an average of 
52% of cells above baseline (cells with serum-free medium). 
 
 
Statistical analysis 
 
Values are expressed as the arithmetic mean ± standard error 
of mean (SEM). The statistical significance of the differences 
between groups was ascertained via one-way ANOVA or two-
way ANOVA (treatment and cell type as main factors), 
followed by Tukey’s multiple comparison test. Migration results 
are expressed as percentage of control (vehicle treatment only). 
All statistical analyses were performed using GraphPad Prism 6 
(GraphPad Software Inc., San Diego, CA, USA). Differences 
were considered statistically significant when p<0.05. 
 
 
RESULTS 
 
ER expression in human MDM subsets 
 
Estrogens initiate cellular signaling pathways via interaction 
with their receptors expressed primarily as two subtypes, ERα 
and ERβ, whose distribution varies with different cell types 
[26]. Recent reports have shown that many of the tissue-specific 
differences in estrogen action are attributable to selective 
binding to each ER subtype. Human macrophages have been 
reported to express both ERα and ERβ [27]; however their 
Gene  Forward primer (5'-3') 
Reverse primer  
(3'-5') 
Annealing 
Temperature 
Hprt TGCTGACCTGCTGGATTACA TTTATGTCCCCTGTTGACTGG 59 
c-Jun GAGCGCCTGATAATCCAGTCC GAAGCCCTCCTGCTCATCTGT 62 
COX2 CATTCCCTTCCTTCGAAATGC GAGAAGGCTTCCAGCTTTTG 61 
CREB1 ACTGATTCCCAAAAGCGAAGG CTTCAATCCTTGGCACTCCTG 61 
ERα GAAGAGGGTGCCAGGCTTTGT CGCCAGACGAGACCAATCATC 64 
ERβ GTTCGACCAAGTGCGGCTCTT TCCCCTCATCCCTGTCCAGAA 65 
ERK2 TGTTGACATTCAACCCACACAA TCGAACTTGAATGGTGCTTCG 61 
Ikβα TGGGCCAGCTGACACTAGAAA GGCCTCCAAACACACAGTCAT 62 
JNK1 AAGCGGGCCTACAGAGAGCTA GGCAAAGATTTGCATCCATGA 61 
NF-κB GCCCAGTGAAGACCACCTCTC AAGCTGAGTTTGCGGAAGGAT 62 
RelA GCTCCTGTGCGTGTCTCCAT TTCTCCTCAATCCGGTGACG 62 
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expression in different macrophages subsets had not been 
evaluated. 
In the current study, qRT-PCR was performed to determine 
estrogen receptor transcription according to macrophage 
polarization. In agreement with previous reports [28], we 
identified the transcripts for both α and β forms of ER in 
primary macrophages (Figure 1). Further, human peripheral 
blood MDM contained significantly higher levels of ERα 
mRNA compared to ERβ (p<0.05). ERβ transcription is 
detected at very low levels in these cells. To examine the 
potential changes in ER transcription as a result of activation 
and differentiation of human peripheral blood MDM, we 
compared ER mRNA levels in M1 (LPS-activated) and M2 
(IL4-activated) MDM with that of unstimulated cells (M). ER 
analysis demonstrated a significant decrease in ERα mRNA 
transcription in M1 macrophage (p<0.05) compared to M and 
M2. Activation of human peripheral blood MDM did not 
significantly alter ERβ in M1 nor ERα in M2 compared to M. 
Therefore, our results suggest that ERα and ERβ are expressed 
differentially depending on macrophage polarization.
 
 
Figure 1. ERα and ERβ mRNA levels in classically (M1, 100 ng/mL LPS) or alternatively (M2, 15 ng/mL IL4) activated human 
macrophages or unstimulated human macrophages (control, M). mRNA levels were determined by qRT-PCR and normalized to the 
housekeeping gene hypoxanthine-guanine-phosphoribosyltransferase (HPRT). Values are represented as mean ± standard error of 
mean of three independent experiments performed in duplicate (final n=3). Statistical analysis with one-way ANOVA, followed by 
Tukey’s multiple comparison test: *p<0.05 vs M, #p<0.05 vs M1. 
  
 
E2 modulates human MDM cytokine production 
 
Having determined that peripheral blood MDM express ERs 
and thus may respond to E2, we sought to investigate the 
influence of E2 on macrophage effector functions, namely the 
production of IL1β, IL6, IL10 and TNFα, in response to this 
hormone. Based on this approach, control (M) peripheral 
blood MDM and M1 and M2 macrophages were treated with E2 
(10-11 M) alone or in combination with the selective ERα 
antagonist MPP (10-6 M), the selective ERβ antagonist PHTPP 
(10-6 M) or with vehicle (DMSO), and cytokine levels were then 
measured by ELISA, in 24 h culture supernatants. 
The basal release of cytokine production in the three cell 
types is depicted in figure 2 (a, c, e, g). IL10 (13.95 ± 1.04 vs 
44.38 ± 0.62 pg/mL) and TNFα (1100.00 ± 32.00 vs 2770.00 ± 
157.00 pg/mL) release was lower, whereas IL1β (177.78 ± 1.01 
vs 94.44 ± 11.11 pg/mL) was higher in M1 macrophage when 
compared to M. No differences were found between M and 
M1 macrophages regarding IL6 release levels. On the other 
hand, IL6 (122985.05 ± 5970.15 vs 36529.85 ± 4738.81 pg/mL) 
and IL10 (62.90 ± 2.84 vs 44.38 ± 0.62 pg/mL) release was 
more pronounced, and TNFα (3214.00 ± 38.00 vs 2770.00 ± 
158.00 pg/mL) and IL1β (98.94 ± 0.65 pg/mL vs 94.44 ± 11.11 
pg/mL) levels were similar in M2 macrophages when compared 
to M.  
In LPS-activated M1 macrophages, IL10 (51.36 ± 4.26 
pg/mL) and IL6 (20223.88 ± 8805.97 pg/mL) release was 
clearly up-regulated by E2 treatment (figure 2b, d). This effect 
of E2 on IL10 seems to be ERα- and ERβ-independent since it 
was unaffected by incubation with either MPP or PHTPP, 
respectively (figure 2b). However, IL6 secretion induced by E2 
was decreased in the presence of MPP and increased in the 
presence of PHTPP (figure 2d). TNFα and IL1 β release in M1 
was unaffected by E2 treatment (figure 2e, f, g, h). 
Furthermore, E2 strongly down-regulated the IL4-polarized 
M2 cell release of IL10 (5.79 ± 0.05 vs 62.90 ± 2.84 pg/mL), 
IL6 (77.69 ± 5.15 vs 122985.05 pg/mL), TNFα (82.00 ± 19.00 
vs 219.50 ± 14.50 pg/mL) and IL1β (2.12 ± 1.21 vs 177.78 ± 
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1.01 pg/mL) (figure 2b, d, f, h). In these cells, cytokine release 
inhibition by E2 was blocked by the ERβ antagonist PHTPP in 
the case of IL6, IL10 and TNFα, and by the ERα antagonist 
MPP in the case of IL1β, IL10 and TNFα.  
 
 
 
 
 
 
Figure 2. Cytokine release according to macrophage polarization states. Peripheral blood monocyte-derived macrophages either unstimulated (M) or 
after polarization with lipopolysaccharide (100 ng/mL, M1) or interleukin (IL) 4 (15 ng/mL, M2) were treated with 17β-estradiol (E2, 10-12 M) alone or in 
combination with the selective estrogen receptor (ER) α antagonist (iERα, 10 -6 M) or the selective ERβ antagonist (10-6 M, iERβ), and appropriate 
controls were made by incubation with vehicle, allowing to determine basal cytokine release (a, c, e, g). The levels of IL10 (a, b), IL6 (c, d), tumor 
necrosis factor (TNF) α (e, f) and IL1β (g, h) were determined in the culture media at the end of the 24 h treatments. Results are presented as mean ± 
standard error of mean (three individual experiments performed in duplicate). Statistical analysis with one-way (a, c, e, g) or two-way ANOVA, followed 
by Tukey’s multiple comparisons test: *p<0.05 vs M control, #p<0.05 vs M1 control (vehicle), σp<0.05 vs M2 control (vehicle), £p<0.05 vs M1 treated 
with E2, §p<0.05 vs M2 treated with E2. 
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E2 alters gene expression profile of human MDM 
 
The presence of ER in human MDM suggests that the 
modulation of inflammatory responses observed after E2 
treatment may occur at the transcriptional level. Thus, we next 
investigated the molecular basis for E2 ability to differentially 
regulate M1 and M2 targets. Accordingly, M1 and M2 cells 
were treated with E2 (10
-11 M) alone or in combination with the 
selective ERα and ERβ antagonists as already described above, 
and the transcription levels of selected inflammation-related 
genes was analyzed by qRT-PCR analysis.  
The MAPK signaling pathway in macrophages is one of the 
most extensively investigated intracellular signaling cascades 
involved in pro-inflammatory responses, the extracellular 
signal-regulated kinases 2 (ERK2) and c-Jun N-terminal kinase 
(JNK) belonging to this family [29]. Two-way ANOVA (main 
factors: treatment and cell type) revealed the significant effect 
of cell type (F1,5 = 6986, p<0.05), treatment (F1,5 = 6896, 
p<0.05) and an interaction between treatment and cell type 
(F1,5 = 6757, p<0.05) on JNK1 transcription (figure 3a). The 
signal intensity of JNK1 gene transcription after 24 h E2 
treatment was significantly higher in M2 cells than that in M1 
cells (p<0.05, Tukey’s), an effect that was found to be ERα- and 
ERβ-dependent (figure 3b). Concerning ERK2 transcription 
level, two-way ANOVA disclosed the significant effect of cell 
type (F1,4 = 23.34, p<0.05) (figure 3c). ERK2 levels were 
significantly higher (p<0.05, Tukey’s) in M1 than in M2 E2-
treated macrophages (and the same tendency was observed 
between M1 and M2 untreated macrophages) and, in 
accordance, modulation of either ER had no effect on ERK2 
transcription (figure 3d).  
Members of the NF-B/Rel family regulate many genes 
involved in immunity and inflammation [30]. The current 
analysis showed the significant effects of treatment (F1,5 = 
12.65, p <0.05), cell type (F1,5 = 10.34, p<0.05) and an 
interaction between treatment and cell type (F1,5 = 44.23, 
p<0.05) on the NF-B (p50) transcription level (figure 3e). The 
NF-B (p50) levels were significantly higher (p<0.05, Tukey’s) 
in E2-treated M2 macrophages than in E2-treated M1 
macrophages or vehicle-treated M2 macrophages. This increase 
in NF-B (p50) expression after E2 treatment in M2 
macrophages was found to be ERα- and ERβ-dependent (figure 
3f). On the other hand, although the ANOVA revealed no 
significant effect of treatment and/or cell type on the expression 
levels of RelA (p65), this NF-B subunit tends to increase in 
M1 cells after E2 treatment (figure 3g, h), an effect that seems to 
be mediated by ERα and ERβ.  
The transcription factor NF-B is maintained in an inactive 
form by its inhibitor IBα, thereby preventing NF-B-induced 
transcription of target genes [31]. Two-way ANOVA unveiled 
the significant effect of treatment (F1,7 = 7.745, p<0.05) on the 
IBα transcription level (figure 3i). IBα levels had a tendency 
to be higher in E2-treated M1 macrophages than in vehicle-
treated M1 macrophages in an ERβ-dependent manner (figure 
3j).  
Along with NF-B, the transcription factor AP1, is also 
known to be involved in the transcriptional regulation of 
inflammatory responses [32]. Analysis showed a significant 
effect of cell type (F1,6 = 10.39, p<0.05), treatment (F1,6 = 
6.847, p<0.05) and an interaction between treatment and cell 
type (F1,6 = 5.994, p<0.05) on c-Jun transcription (figure 3k). 
E2 treatment significantly (p<0.05, Tukey’s) increased c-Jun 
gene transcription in M2 macrophages in comparison to vehicle-
treated M2 macrophages and no effect was observed in M1 
cells. This increase in c-Jun expression mediated by E2 was 
found to be ERβ-dependent (p<0.05, Tukey’s) (figure 3l).  
The cAMP response element-binding protein (CREB) 1 is a 
common target of many signaling pathways and a key 
transcription factor in processes such as inflammation and cell 
migration [33, 34]. Two-way ANOVA revealed the significant 
effect of cell type (F1,6 = 19.92, p<0.05) and an interaction 
between treatment and cell type (F1,6 = 10.21, p<0.05) on 
CREB1 transcription (figure 2m). The signal intensity of 
CREB1 gene transcription after 24 h E2 treatment was 
significantly higher (p<0.05, Tukey’s) in M1 cells than that in 
M2 cells and no effect was observed after treatment with ER 
antagonists. 
Inflammatory responses are mediated in part by pro-
inflammatory cytokines and induction of cyclooxygenase 
(COX) 2 [35]. Two-way ANOVA revealed a significant effect 
of cell type (F1,5 = 34.73, p<0.05), treatment (F1,5 = 22.01; 
p<0.05) and an interaction between treatment and cell type 
(F1,5 = 32.85, p<0.05) on COX2 transcription (figure 3O). E2 
treatment significantly induced COX2 transcription in M1 
macrophages (p<0.05, Tukey’s) and did not modify COX2 
levels in M2 macrophages. This increase in COX2 transcription 
in M1 macrophages after E2 treatment was found to be ERβ-
dependent (p<0.05, Turkey’s) (figure 3p).  
 
E2 regulates MDM cell migration 
 
In order to explore the influence of E2 on migratory properties 
of human MDM upon different polarization states, 
differentiated cells were incubated with E2 and were allowed to 
migrate towards a chemotactic stimulus. For this purpose, 
transmigration chamber assays were performed.  
Our results showed that migration of classically- and 
alternatively-activated untreated macrophages towards RPMI-
1640 medium phenol-red free supplemented with 10% FBS was 
significantly decreased (72.6 ± 4.6% and 66.4 ± 4.5% of the 
control value, respectively) as compared to non-stimulated M 
macrophages (p<0.05) (figure 4a). Two-way ANOVA revealed 
a significant effect of cell type (F1,12 = 6.083, p<0.05), 
treatment (F1,12 = 4.802, p<0.05) and an interaction between 
treatment and cell type (F1,12 =6.083, p<0.05) on polarized 
MDM migration (figure 4b). The migration capacity of E2-
treated M2 macrophage toward the 10% FBS stimulus was 90% 
increased as compared to vehicle-treated M2 macrophage, and 
when comparing to E2-treated M1 macrophage migrated about 
95% more (p<0.05, Tukey’s). This increase in migration 
stimulated by E2 in M2 cells seems to be independent of ERα 
and ERβ. 
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Figure 3. Effect of 17β-estradiol on the transcription of genes involved in macrophage inflammatory responses. Peripheral blood monocyte-derived 
macrophages after polarization with lipopolysaccharide (100 ng/mL, M1) or interleukin (IL) 4 (15 ng/mL, M2) were treated with 17β- estradiol (E2, 10-12 
M) alone or in combination with the selective estrogen receptor (ER) α antagonist (iERα, 10 -6 M) or the selective ERβ antagonist (10-6 M, iERβ), and 
appropriate controls were made by incubation with vehicle. mRNA levels were determined by qRT-PCR and normalized to the housekeeping gene 
(hypoxanthine-guanine-phosphoribosyltransferase, HPRT). Values are represented as mean ± standard error of mean of duplicated samples and are 
representative of three independent experiments. Statistical analysis with two-way ANOVA, followed by Tukey’s multiple comparison test: #p<0.05 vs 
M1 control (vehicle); σp<0.05 vs M2 control (vehicle); £p<0.05 vs M1 treated with E2; §p<0.05 vs M2 treated with E2. COX2, cyclooxygenase 2; CREB1, 
cAMP responsive element binding protein 1; ERK2, extracellular signal-regulated kinases 2; IBα, inhibitor of Bα; JNK, c-Jun N-terminal kinases; NF-
B, nuclear factor-B. 
 
 
 
Figure 4. Estrogen regulation of peripheral blood monocyte-derived macrophages migration, either unstimulated (M) or after polarization with 
lipopolysaccharide (100 ng/mL, M1) or interleukin (IL) 4 (15 ng/mL, M2). M1 and M2 macrophages were loaded into the upper wells of migration 
microchambers and were treated with 17β-estradiol (E2, 10-12 M) alone or in combination with the selective estrogen receptor (ER) α antagonist (iERα, 10-
6 M) or the selective ERβ antagonist (10-6 M, iERβ), and appropriate controls were made by incubation with vehicle. The lower wells were filled with 
10% FBS RPMI-1640 medium. Cell migration was allowed for 24h. Values are represented as mean of the percentage of control group ± standard error of 
mean from two independent experiments. The absolute control values (Abs 480/520 nm) were 180.73 ± 16.99, 110.06 ± 9.14 and 132.94 ± 18.47 for M, 
M1 and M2 cells, respectively. Statistical analysis with one-way (a) or two-way ANOVA, followed by Tukey’s multiple comparisons test: *p<0.05 vs 
M; σp<0.05 vs control M2 (vehicle), £p<0.05 vs M1 treated with E2.  
 
 
DISCUSSION 
 
Several investigations strongly support that estrogens’ actions 
go far beyond those expected from their designation as a sex 
hormone; in fact, they act as transcriptional activators regulating 
important biological functions in almost every tissues of the 
body [8]. Thereby, the study of estrogens’ action on the 
modulation of human macrophage function is of substantial 
interest since these versatile cells are implicated in the 
regulation of immune response and are consequently relevant to 
pathogenesis of many diseases [36]. 
During the course of the inflammatory response, phenotypic 
switching of macrophages from an M1 to an M2 program has 
been observed, underscoring the dual role of macrophages in 
initiating and subsequently resolving inflammation. 
Additionally, Kramer et al. [9] have found that absence of 
estrogen does not have a dramatic effect on the amount of ER 
protein, suggesting that estrogens do not regulate their own 
receptors in monocyte-derived macrophages. However, their 
expression in different macrophage subsets, a feature that may 
be critical for determining their responsiveness to estrogenic 
stimuli, had not been fully evaluated. 
In the present study, we demonstrated that ERα and ERβ 
mRNA are differently expressed in different stages of 
macrophage polarization, in monocyte-derived macrophages 
(MDM) from postmenopausal women. Using qRT-PCR, we 
verified that ERα mRNA was expressed at higher levels than 
ERβ in macrophages that had been differentiated with IL4 for 7 
days or with LPS for 24 h at the end of differentiation period. 
ERβ mRNA is expressed at very low levels in both of these 
cells. Previous studies have shown a consistence between 
mRNA transcription of ERs and total protein levels [37, 38]. 
This finding suggests that macrophage cells may respond to 
estrogen primarily through ERα rather than ERβ. Corroborating 
this fact, in different mammalian models, the preponderance of 
ERα gene over the ERβ gene is accepted to be a mechanism 
controlling the effects of E2 on the immune system [8, 39]. In 
fact, many immune effects attributed to E2 in macrophages are 
thought to be mediated through ERα and not ERβ [20, 40, 41]. 
Phiel et al. [42] demonstrated that ERα is increased in 
monocytes from postmenopausal women which may result in 
altered estrogen responsiveness compared with monocytes from 
premenopausal women. 
It is widely accepted that ER α/β signaling largely exerts 
natural anti-inflammatory effects in immune cells of the 
monocyte lineage [43]. Thus, a decline in circulating E2 could 
favor a more pro-inflammatory environment or exacerbate a 
status of preexisting inflammation. In fact, macrophage 
responses are not only determined by the polarization state but 
deeply depend on the specific micro-environmental conditions 
in which cells were prior to their activation. Regarding the 
effects of E2 on macrophage effector functions, conflicting 
results have been reported from several lines of evidence. While 
in vitro experiments have suggested that E2 exerts anti-
inflammatory properties on monocyte/macrophage cell lines or 
microglia cells, following activation with LPS [10, 44], opposite 
results have been independently reported by analyzing the in 
vivo effects of estrogens on the same cell populations [45, 46]. 
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Very little work has been conducted examining the effect of E2 
on cytokine expression in human MDM cells.  
Here, we found that upon stimulation with LPS, M1 
macrophages secreted higher amounts of IL1β, similar amounts 
of IL6 and lesser amounts of TNFα and IL10 comparing to 
unstimulated macrophages. This profile of cytokine production 
displayed by LPS-polarized macrophages seems to reveal a 
certain inability to recapitulate typical M1 responses, as one 
would expect increases in IL6 and TNFα following stimulation. 
Rachón et al. [47] found that among the majority of 
postmenopausal women, IL6 expression may be present in non-
stimulated PBMC isolated directly from venous blood, which 
suggests the possibility of an endogenous activation of these 
cells in vivo. The absence of circulating estrogens in the 
postmenopause may play a role, explaining why the production 
of cytokines may be in the stimulated state, thus not increasing 
further in response to LPS. 
Long-term E2 treatment at physiological concentrations [48] 
enhanced the M1 release of IL10 and much more of IL6 
(through ERα-dependent mechanisms for the latter) without 
change in TNFα or IL1β transcription. This is in accordance 
with previous published data showing that administration of E2 
to ovariectomized female mice markedly increases the 
expression of numerous inflammatory cytokines by 
monocytes/macrophages in response to LPS activation ex vivo 
[45]. However, both the dose (postmenopausal/metestrus levels 
compared with midfollicular phase to pregnancy levels) and the 
timing (before, during or after macrophage activation) of E2 
treatment may be critical [8, 49, 50]. In this regard, the target of 
the hormone’s action may be the early-phase activation of LPS 
signaling [48]. This also suggests that once exposed to an 
estrogen-deprived environment, re-exposure to E2 at low levels 
is unable to reverse the acquired pro-inflammatory priming. 
This may represent that the lack/decrease of estrogen signaling 
may render subjects to a more pro-inflammatory situation, 
which might contribute to the manifestation of chronic 
inflammatory diseases. One important addition to this 
discussion is the available, although scarce, information about 
the spontaneous decreases in cytokine activity with natural 
menopause, suggesting that stimulatory effects of estrogen on 
cytokine production may perhaps only be elicited in non-
physiological conditions, e.g, systemic inflammatory state [51], 
as supported by the findings of Gregory et al. [52]. It is known 
from the literature that IL4 is the prototypical direct inducer of 
M2 macrophages which produce high levels of IL10, TGFβ and 
low levels of IL12 and have the capability to suppress the 
production of pro-inflammatory mediators by human monocytes 
activated in vitro, at least at the mRNA level [53, 54]. 
Corroborating this evidence, in the present work we also 
observed an enhanced production of IL10 and a decrease in 
IL1β comparing to Mϕ and/or M1 macrophages; however, we 
also found that these cells released higher amounts of IL6 and 
TNFα. Again, we can speculate that previous exposure to an 
estrogen poor environment may change cytokine release from 
the cells to a more pro-inflammatory profile. This hypothesis is 
reinforced from observations of Hart et al. [55]. This increase in 
the release of inflammatory cytokines by cells involved in the 
resolution of inflammation may exacerbate the inflammatory 
state that accompanies the decline of estrogens namely in 
menopause.  
Nonetheless, the relationship between E2 and cytokine release 
is far from being simple. Most often, E2 effects on macrophages 
are primarily repressive, by reducing the expression of genes for 
cytokines or modulating other inflammatory mediators by the 
ER-dependent and/or non-genomic pathways in response to 
inflammatory signals [20, 56, 57]. Further, the majority of 
studies only addressed the effect of E2 on classically activated 
M1 cells and less is known about the effect on alternatively-
activated macrophages.  
There may be several distinct pathways by which E2 may 
affect cytokine gene expression, eliciting either net increases or 
decreases in cytokine production, depending on the activation of 
these pathways in the individual cellular context. At this time, 
we focused on the transcription level of several genes with 
special attention to the signaling factors such as JNK1, ERK2, 
COX2, nuclear transcription factors like AP1 (c-Jun), NF-B 
(p50 and p65) and its inhibitor IBα and CREB1, to try to 
understand the molecular basis of E2 action.  
Here, we showed a tendency towards an increase in ERK2 
transcription in M1 E2-treated cells as well as a clear effect of E2 
treatment in favor of JNK1 and p65 NF-B transcription which 
may be involved in the observed increase of IL10 production. 
Indeed, Liu et al. [58] demonstrated that p65 NF-B, ERK1/2 
and JNK, were all involved in LPS-induced IL10 expression. 
These signaling pathways might also regulate IL6 and TNFα. 
Moreover, in mouse activated macrophages prostaglandin 
E2 also upregulates the level of IL10 [58]. In line with this, we 
observed a significant increase in COX2 transcription upon E2 
treatment [59]. Interestingly, many of these effects in gene 
transcription seem to be mediated by ERβ, highlighting that 
although ERα is expressed in substantially higher levels and 
most estrogens effects have been related to this isoform, ERβ 
also plays a role. 
In M2 cells, the inhibitory effect of E2 in IL6, TNFα and IL1β 
expression may be a result of E2-ER mediated binding, and 
consequently blocking, NF-B, an effect reported in several in 
vitro studies [60, 61]. In good agreement with this, we observed 
in M2 E2-treated cells an increase in p50 NF-B transcription 
(and the same tendency was observed in IBα). As homodimers 
of the NF-B p50 can function as transcriptional repressors and 
IBα may inhibit the transcriptional activity of p65 NF-B 
complexes [62], E2 treatment in M2 cells may be linked to 
impaired expression of these NF-B-dependent genes.  
Central to host-defense responses is leukocyte (e.g. monocyte 
and macrophage) recruitment to the sites of injury. In this study 
we show that LPS- or IL4-stimulated MDM have lower 
capacity to cross membranes in the transmigration chamber 
assays than unstimulated macrophages that readily transmigrate 
to the bottom of the plate. In line with this finding, in 2008 
Bradfield et al. [63] have shown that LPS activation leads to an 
arrest of the monocyte on the lumenal surface whereas non-
activated monocytes readily transmigrate across the 
endothelium. Several other studies that look at the effects of 
LPS on monocyte migration have been published over the past 
decade, which appear contradictory [64, 65]. More recently 
Tajima et al. [66] have established that in macrophages, LPS 
stimulates prostaglandin signaling initiating early migration as 
well as leading to induction of MCP-1, which contributes to a 
later phase migration. 
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Figure 5. A model illustrating the putative regulation of blood monocyte-derived macrophages (M) after classically (M1; LPS, 100 
ng/mL) or alternatively (M2; IL4, 15 ng/mL) polarization by 17β-estradiol (E2). Estrogen receptor (ER) α was expressed at higher 
levels than ERβ in M difference that remained present after polarization. M1 macrophages secreted higher amounts of IL1β, similar 
of IL6 and lesser amounts of IL10 and TNFα than unstimulated M macrophages. E2 treatment at physiological concentrations 
enhanced M1 release of IL10 and much more IL6. M2 macrophages secreted higher IL10 and IL6 amounts than M, and E2 treatment 
decreased the release of all cytokines evaluated. E2 increased migration only in M2. The evaluation of the transcription of several 
genes namely JNK1, ERK2, COX2, nuclear transcription factors like AP1 (c-Jun), NF-B (p50 and p65) and its inhibitor IBα and 
CREB1 and effects mediated by E2 treatment appear highlighted. COX2, cyclooxygenase 2; CREB1, cAMP responsive element 
binding protein 1; E2, 17β-estradiol;  ERK2, extracellular signal-regulated kinases 2; IL, interleukin; IBα, inhibitor of Bα; JNK1, c-
Jun N-terminal kinases 1; LPS, lipopolysaccharides; M, control macrophages; M1, classically activated macrophages; M2, 
alternatively activated macrophages; NF-B, nuclear factor-B; TNFα, tumor necrosis α; ↑, increase; ↓, decrease. Estrogen receptor α 
and β dependent effects appear as the subscripts ERα and ERβ, respectively. 
 
 
However, to date there is a paucity of evidence about the role 
of E2 in the migratory capability of clearly differentiated human 
macrophages. In our study, concerning M1 macrophages, E2 did 
not alter the migratory capacity of these cells which may be 
consistent with their rear guard role against pathogen invasion. 
Concerning M2 macrophages, as far as we know, this is the first 
study to document the E2 stimulation in macrophage migration 
under static conditions, at a low concentration. As notably 
reviewed by Straub, E2 at high levels inhibits migration of 
innate immune cells to the site of inflammation, although this is 
mostly reported in conditions of active chronic inflammation. In 
vitro and in vivo studies, point toward a marked inhibitory effect 
of high levels of E2 on migration of leukocytes into inflamed 
areas, particularly neutrophils and monocytes, what was 
accompanied by less severe inflammation [8]. 
Here, we suggest that low E2 levels support trafficking of 
“healing” M2 cells to the inflammation site by serving as a 
selective stimulus and “phenotype-shaping gate” for 
macrophages en route to the injured site. Recently, several 
reports have shown that MAPKs, mainly ERK1/2, p38 and 
JNK1, are involved in chemotaxis induced by serum in 
leukocytes and smooth muscle cells [67] In the present work, 
we observed that E2 significantly increased JNK1 transcription a 
possible mechanism contributing to increased migration in M2 
cells.  
The approach used by our study consisted of comparing 
between E2 and co-treatment with ER antagonists namely MPP 
(iERα) and PHTPP (iERβ), revealing the involvement of each 
receptor subtype in the described effects. As demonstrated for 
E2, the effect of treatment with iERs varies according to cell 
type, thereby granting the possibility to selectively inhibit or 
 CHAPTER III 
 
 
 
 
- 52 - 
stimulate estrogen-like actions in various tissues. Specifically, 
our results provide evidence of ERβ functionality on 
macrophage subtypes. However, it should be noted that a part of 
estrogens effects are independent of ERs suggesting the 
involvement of non-classical estrogen signaling, which is 
supported by the modification of the second messengers and 
transcription factor here evaluated.  Although protein levels and 
phosphorylation status were not determined for these pathways, 
the effects observed along with the demonstration of regulation 
by ER inhibition establishes a role for estrogens in their 
regulation at least at a transcriptional level. Specifically, one 
cannot exclude the participation of the nonclassical ER GPR30 
to E2 effects on macrophages. Moreover, it is necessary to point 
out that dependent on the concentration used, ER antagonists 
may behave as agonists (which is true for higher 
concentrations). However, most of our results reflect that they 
were indeed inhibiting E2’s effect showing their antagonistic 
action and highlighting that ERs are mediating the effects.  
We also provide further evidence that physiological levels of 
E2 influence the inflammatory status of macrophages and 
consequently the capability to orchestrate inflammatory and 
immune responses (Figure 5). This report supports the view that 
both pro- and anti-inflammatory programs can co-exist within 
M1 and M2 macrophages, as recently proposed [68], instead of 
being mutually antagonistic. This affords a framework to 
provide homeostasis by “pulling” the cell in opposite directions 
[69], to which coincident or previous exposure to estrogens may 
be determining. 
In summary, the results presented in this study open a new 
avenue into the possible molecular mechanism by which E2 may 
regulate immune cells, particularly macrophage homeostasis. 
The interference in MDM functions by E2 may constitute a 
valuable target to modulate inflammation pathophysiology. 
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The global prevalence of metabolic diseases like T2D and their colossal economic and social costs 
represent a major public health concern for present societies, despite medical and political efforts to 
control their increased prevalence. This growing trend has been attributed to a conjunction of genetic and 
environmental factors [153]. Likewise, shifts in population genetics are unlikely to occur on a time scale 
that explains the recent deterioration in human metabolic health. The WHO estimates that “as much as 
24% of global disease is caused by environmental exposures that can be adverted” [154]. As such, 
increasing attention has been turned to the identification of additional factors that may impact on energy 
metabolism, including exposure to chemical pollutants.  
In fact, in the modern world, the environment has been largely affected by an ever increasing number of 
synthetic pollutants, such as pesticides, organophosphates, polychlorinated bisphenyls, phthalates, and 
solvents, among others, some of them with estrogenic activity [155]. These may permeate the diet, the air 
and the ground. Indeed, the exponential rise of obesity-related pathologies worldwide may be associated 
with the marked increase of toxic chemicals in the environment [156, 157]. This issue is immensely 
challenging as the list of chemicals to which humans are exposed continues to grow and is now 
somewhere near 100,000 distinct compounds.  
First articulated in 1992, the theory of endocrine disruption postulates that exogenous chemicals can 
modulate homeostasis by interfering with action of endogenous hormonal axis. Some endocrine 
disruptors were designed to have long half-lives and therefore are persistent contaminants, do not decay 
easily, may not be metabolized, or may be broken down into more toxic compounds. Others such as BPA 
and phthalates, although not very persistent in the environment are so widespread in their use that there 
is a prolonged human exposure [158]. These man-made chemicals have been used extensively in 
agricultural, industrial and manufacturing processes. Environmental and human exposure to XEs has been 
the subject of scientific investigation and political regulation for almost 40 years. The Stockholm 
Convention on POPs, signed in 2001 and effective from May 2004, is a global treaty to protect human 
health and the environment from chemicals that remain in the environment for long periods, become 
widely distributed geographically, accumulate in the fatty tissue of humans and wildlife, and have adverse 
effects on human health or in the environment. However, they are still ubiquitous in our environment, 
especially in the food chain [159]. Some highly prevalent endocrine disruptors have immunosuppressive, 
oxidative, pro-inflammatory, neuroendocrine, metabolic and epigenetic effects [160, 161].  
The interest in molecules that can interfere with estrogen signaling, or XEs,  has been growing, either to 
understand why exposure to certain chemicals can influence the incidence of estrogen-dependent 
diseases or to use them in order to change estrogen signaling in a convenient way. The understanding of 
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the mechanisms of action and clinical effects of XEs, as endocrine and metabolic disruptors, has increased 
significantly over a decade: yet, it is far from being complete [161]. Another relevant question is whether 
current approaches to risk assessment and regulatory control of exposure to XEs are adequate to protect 
the population against diseases.  
In the case of dietary intake, people with increased food intake, such as obese individuals, may need 
special attention. Moreover, it is well accepted that humans bioaccumulate these lipophilic pollutants in 
the AT for many years and because of its highly resistance to metabolic degradation levels become 
increaselly elevated [162]. At the same time, AT may be an endogenous source of these compounds. For 
these reasons and because the different AT depots may have somewhat different endocrine functions, it is 
important to know whether or not XEs distribute equally throughout all AT and ultimately to determine 
how levels of these compounds influence the local AT dynamics in an obese state. 
Our initial approach aimed at studying the patterns of accumulation and variation in selected XEs (namely 
DDT and its metabolites, α-, β- and - hexachlorocyclohexane (HCH), hexachlorobenzene (HCB) and aldrin) 
in plasma and AT samples in obese pre- and postmenopausal women. XEs are pervasive in this obese 
population (Chapter IIA), confirming their bioaccumulation with a higher detection percentage in both AT 
depots than plasma in pre- and postmenopausal women. Although some recent studies have suggested 
that some heterogeneity exist with respect to the distribution of XEs across AT depots [163, 164], 
investigators always denoted the need of more studies to confirm that evidence because of the limited 
number of subjects that were studied. Our data strongly reinforces the heterogeneity both in the profile 
of distribution and concentration of XEs in AT depots, with a robust number of subjects studied. Until 
recently, it has been proposed that the variability of the stored amount of particular XEs in the AT, which 
can range over several orders of magnitude, depends on dietary exposure, on individual predisposition to 
store these substances and on the differential lipophilicity of various XEs [163-166]. We additionally 
suggest that hormonal status is an important determinant for the differences in XEs accumulation 
between AT depots and in each depot, since premenopausal women accumulate XEs preferentially in vAT. 
Following menopause and the decline in circulating E2, women accumulate intra-abdominal AT and tend 
to develop male-pattern adiposity [167]. In the present study, this AT redistribution is accompanied by 
changes of XEs pattern of accumulation, XE levels being similar in both scAT and vAT, and significantly 
higher than those found in premenopausal women scAT, probably reflecting a concentration of XEs in 
scAT. Firstly, although this may seem paradoxical, it is not surprising because the total amount of scAT 
mass decreases considerably [149], thereby leading to an increased concentration of XEs in this location. 
Secondly, this is an important finding with practical implications because it suggests that scAT, despite 
being an easily accessible compartment for determination of contamination levels, is not representative of 
the XE distribution in deeper AT depots across the general population, as suggested by different groups 
[168, 169]. On the other hand, we believe that the higher accumulation of XEs observed in premenopausal 
vAT is of paramount importance since this highly metabolically active tissue is held as the main impeller of 
  
SUMMARIZING DISCUSSION 
 
 
- 75 - 
metabolic dysfunction progression. As known, it has been demonstrated that accumulation of vAT is 
correlated with increased risk and mortality from diabetes and CDV [170]. Our data supports that 
accumulation of pollutants with endocrine disrupting capacity might be implicated in metabolic 
dysfunction associated with increased vAT. Herein, XEs in vAT of premenopausal women were found to be 
more tightly associated with markers of worst metabolic profile compared to XEs in scAT, namely glucose 
homeostasis and inflammatory parameters, suggesting that the presence of these compounds in vAT 
contributes to local toxicity and dysfunction and potentially favors the metabolic complications associated 
with obesity [149]. Furthermore, this finding strengthens our theory that the biological effects of XEs 
might differ between AT compartments. 
Although XEs accumulate mainly in AT, collecting AT is difficult in practice. Therefore most epidemiological 
studies of XEs have used their circulating concentrations as a marker of body burden, as circulating XE 
concentrations are reportedly strongly correlated to those in AT [168, 169]. Contrary to this notion, we 
noted that plasma levels of XEs did not reflect total levels nor the pattern of compoundsaccumulation in 
AT compartments, highlighting that using plasma XE levels to estimate exposure may be misleading. On 
the other hand, several observations both in humans and animals suggest that the release of pollutants 
from AT is an important source of blood XEs. In humans, most of the evidence has been gathered from 
studies on drastic weight loss in obese individuals. Several independent studies demonstrated a positive 
correlation between long-term weight changes and XE plasma concentrations [168, 171, 172]. In our point 
of view, plasma XEs may reflect AT dysfunction. Recently, Gauthier et al. [173] demonstrated the 
relationship of POPs, some with estrogenic activity, with the variation in metabolic risk observed among 
obese individuals, showing that the MHO phenotype is associated with lower plasma levels of POPs as 
compared with MAO subjects. In that report, the authors drew attention to the need to assess the levels 
of POPs in different AT compartments (i.e., scAT and vAT), to provide better understanding on the reason 
for the lower plasma POP concentrations observed in MHO compared to MAO women. In a discussion of 
the publication of Gauthier et al. [173] (Chapter IIB), we propose that the higher plasma levels of POPs in 
MAO may arise from dysfunctional vAT, probably after imposing local toxicity. We provide further 
evidence that this seems to be true especially for the vAT of premenopausal women, in which the sum of 
XEs (∑XEs) in plasma is positively correlated with ∑XEs in vAT and with vAT adipocyte area, a known 
marker of adipocyte dysfunction. Another critical issue is whether the release of XEs from the AT could be 
implicated in metabolic deterioration, eventually through maintaining their availability to exert toxicity in 
other organs and tissues, because once XEs return to circulation they become free to act in distant targets 
[149]. 
Initially known for their ability to promote cancer and affect reproductive functions [174], within the last 
few years, questions and concerns have also focused on the involvement of XEs in the dramatic rise of  
metabolic disorders incidence, such as obesity and T2D. More recently XEs have been associated with 
different cardiometabolic risk factors, including insulin resistance, low HDL-cholesterol, elevated plasma 
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triglycerides and high blood pressure [5, 175-177]. However, most studies have focused on the effect 
modification of a single risk factor, and few link XEs with the complications arising with obesity, when it is 
already installed.  
The Framingham Risk Score is the most commonly used scoring system aiming at predicting the risk of 
CVD, that uses age, gender, smoking history, blood pressure, HDL-cholesterol, low density lipoprotein 
(LDL)-cholesterol, and blood glucose levels to estimate coronary event risk over the course of ten years 
among individuals without previously diagnosed coronary heart disease [178]. Here, we demonstrate 
using the Framingham Risk Score that in premenopausal women, plasma concentrations of XEs may 
partialy explain variability in CVD risk. Our regression model indicated a statistically significant association 
for plasma XEs, along with known risk factors such as inflammation and number of years of obesity, on the 
premenopausal CVD risk. This finding also suggests that environmental XEs might be able to increase the 
disease burden of CVD at a population level. More importantly, the absence of association between XEs 
and inflammation and/or CVD risk among postmenopausal women could indicate, on one hand, that the 
presence of conserved signaling by estrogens is a necessary factor for XEs to increase the risk of 
inflammation and CVD risk. On the other hand, the worsening of the metabolic degradation that XEs can 
provide in premenopausal may have a potential role in the later development of cardiometabolic disease 
in obese women. Then, it is possible that even though XEs might contribute to establishment of increased 
CVD risk in postmenopausal women, we no longer have an association window that allows this 
demonstration.  
Our results imply that the endocrine disruptor character of these compounds may compromise the well 
documented cardioprotective action of estrogens in women. Indeed, epidemiological and experimental 
animal and cellular models have provided intriguing preliminary evidence to suggest a potential 
contribution of XEs to the pathogenesis of CVD [179-182]. However, precise causal relationships or specific 
mechanisms are yet unknown.  
Additionally, the natural increase in cardiometabolic risk after menopause is paralleled by the 
redistribution of body fat, contributing from our point of view to the concentration of XEs on scAT, and 
perhaps extend metabolic dysfunction to this AT localization. It is the dysfunction, rather than the amount 
of AT that appears to be responsible for generating a state of low-grade inflammation and metabolic 
abnormalities [183]. Accordingly, perpetuating the state of positive energy balance and under the chronic 
pressure to store calories, the adipogenic capacity within scAT may falter, leading to overly hypertrophied 
adipocytes, which inappropriately release free fatty acids and overproduce pro-inflammatory adipokines 
[184]. Despite this attempt to accomplashish the storage of excess energy, scAT storage capacity is 
compromised and free fatty acids are relayed to the vAT depot, which is favored by the decrease in E2 
observed in menopause. Thus, an increase of vAT may be a marker for the compromised ability of scAT to 
store excess energy. This observation is rather worring as the release of XEs from scAT may also occur, and 
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may contribute to a further exacerbation of the metabolic dysfunction. Alltogether, these results point 
towards the occurrence of changes in XE toxicokinetics with menopausal status and implicate plasma XEs 
as possible biomarkers of AT functionality.  
An increase in the volume of AT leads to its infiltration by monocytes and macrophages [36]. On the other 
hand, it is well accepted that the inflammatory response, mainly related to macrophages, is involved in 
the development of metabolic disease [185]. Particularly in obesity, increased accumulation of 
macrophages is a hallmark of a pro-inflammatory state that links obesity with systemic inflammation [36]. 
Thus, AT participation in inflammation is attributed largely to the inflammatory actions of bone marrow 
monocyte-derived macrophages populations [36]. Moreover, adipocyte-macrophage interaction 
augments inflammatory changes in AT leading to expression of a variety of chemokines in the AT. Among 
these, MCP-1 plays a pivotal role in obesity-related macrophage infiltration into AT [186, 187]. 
Additionally, it has been proposed that XEs in AT can be involved in inflammatory activation/perpetuation 
[149-151, 188]. Herein (Chapter II), we observed that in premenopausal women, the increase in plasma 
XEs was positively correlated with MCP-1 and, on the other hand, the concentration of XEs in AT, mainly in 
vAT location, was associated with increased number of monocytes in circulation, a possible intermediate 
step to their migration to the AT. This reinforces the hypothesis that the contribution of XE exposure to 
the increasing rate of metabolic disorders may be mediated by their effects on the immune system. 
Another key point of our work was to try to understand the mechanisms involved in the possible link 
between XE actions on the immune system and the development of the state of chronic low-grade 
inflammation and metabolic dysfunction associated with obesity. Indeed, AT macrophages have received 
special attention regarding the immune cells involved. To orchestrate the inflammatory process in the AT, 
macrophages may exist on a spectrum of diverse phenotypes, from M1 to M2. It is well accepted that the 
environmental conditions, degree and type of the inflammatory process will essentially drive their 
polarization to either M1 or M2 macrophages and consequently influence inflammation termination or 
resolution. Estrogens and environmental estrogens have been reported to interfere with and disrupt the 
immune system, namely modulating the function of macrophages. An incomplete understanding of the 
tissue-specific effects of hormone action, and ER distribution and function, contribute to our confusion 
and failure to advance therapeutic strategies to combat estrogen-influenced pathologies [189].  
The models used to study human macrophage polarization are limited and gold standard protocols for 
generating M1/M2 phenotypes in vitro are laking. Accordingly, we used human monocyte-derived 
macrophages that have been spontaneously differentiated in vitro when activated with M1-associated 
(LPS) or M2-associated (IL4) stimuli. Since tissue macrophages are difficult to obtain and handle, this 
experimental model may be used as a ‘‘surrogate’’ to study them. On the other hand, an advantage of 
using these cells is that they generate a heterogeneous starting population that reflects the features of 
plasticity of tissue macrophages. Curiously, such heterogeneity was observed in our study, as reported in 
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Chapter III and Chapter IV, and is consistent with growing evidence that macrophage populations in vivo 
tend to contain concomitantly the characteristics of different differentially activated cells [190]. 
Moreover, the peripheral blood mononuclear cells from healthy postmenopausal women donors were 
used to limit the influence of endogenous estrogens levels on study endpoints.  
With regard to cells of the myeloid linage, there is evidence that estrogens modulate main activities, such 
as maturation, differentiation and migration and it has been demonstrated that monocytes express more 
ERβ while macrophages expresses more ERα [128, 191]. While the contribution of other nuclear receptors 
to macrophage polarization in different settings is well stablished [192, 193], until now, ER expression in 
human macrophages in relation to their activation status, a feature that may be critical to determine their 
responsiveness to estrogen stimuli, had not been evaluated.  
In Chapter III, we found the ER transcription profile to be significantly affected by different stimuli. In 
particular, M1 and M2 macrophages expressed higher ERα levels than ERβ, the latter being expressed at 
very low levels in both cell subtypes. Hence, ER-mediated responsiveness appears to be dependent on the 
macrophage activation status. On the other hand, this finding may suggest that macrophages may 
respond to estrogens primarily through ERα rather than ERβ. Corroborating this idea is the observation of 
Ribas et al. [194] who observed that hematopoietic/myeloid-specific deletion of ERα induces defects in 
macrophage function along with abnormal tissue inflammation and insulin resistance, further suggesting 
that macrophage ERα is involved in the control of the inflammatory response.  
Thus, it becomes evident that these cells may also constitute targets of XE actions. Therefore, through the 
present work we also hypothesize that the immunomodultory effects of XEs may be crtitical for 
cardiometabolic dysfunction. Among environmental estrogens, plastic-derived XEs, because of their 
widespread use in daily life making them measurable in the circulation of almost all individuals in the 
industrialized world [195, 196], may accordingly have a plausible effect on macrophage biological 
dynamics, providing a possible mechanism linking inflammation arising in the AT and the exposure to 
these compounds. 
This impelled us to test the immunomodulatory effect of XEs - BPA, DBP and DEHP - in concentrations 
similar to those in which they are found in the environment [197, 198], in human M1 or M2 macrophages. 
Moreover, to understand how XEs interfere with the immune system, it is necessary to understand how 
natural hormones affect these cells. Therefore, comparisons with E2 were made whenever necessary.  
Firstly, in Chapter III we verified that M1 and M2 macrophages have lower migratory capacity than 
unstimulated macrophages. To date there is a paucity of evidence about the influence of E2 and XEs in the 
migratory capability of differentiated human macrophages. With respect to M1 macrophages, XEs did not 
modify the migration capacity of these cells, mimicking E2 effect. Concerning M2 macrophages, E2 
increased migratory capacity and BPA and the studied phthalates (Chapter IV) mimicked the E2 effect. This 
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is an interesting finding, because although these compounds may cause local tissue inflammation, they did 
not compromise the movement of circulating pro-inflammatory cells, and so did not interfere with their 
role in innate immunity [199].  
Regarding M2 macrophages, as far as we know, this is the first time that stimulation of M2 macrophage 
migration by E2 has been documented. XEs tended to increase migration, again, mimicking the effect of E2. 
This selective effect, independent of ERs, may favor the arrival of M2 macrophages on tissues and sites of 
inflammation, denoting an immune modulatory character of these compounds. Another plausible 
hypothesis is that M1 macrophages are actively retained within the AT in response to XEs. Evidence of the 
detrimental role of M1 macrophages in promoting AT dysfunction has been reported in several studies 
[42, 200, 201].  
A portfolio of cytokines is central to the role of macrophages as sentries of the innate immune system.  
Cytokines are small soluble proteins that confer instructions and mediate communication among immune 
and non-immune cells and deregulated cytokine secretion is implicated in several disease states [202]. 
Very little work has been conducted examining the effect of E2 and XEs on cytokine expression in human 
macrophages. Thus, firstly we characterized the chemokine/cytokine release profile of unstimulated (Mᶲ), 
M1 and M2 macrophages. We verified a certain inability of M1 cells to recapitulate typical M1 responses 
because, although they secreted higher amounts of IL1β, they also secreted similar amounts of IL6 and 
lesser of TNF-α and IL10 comparing to Mᶲ (Chapter III). Accordingly, we suggest the possibility of an 
endogenous activation of these cells in vivo, due to the absence of circulating estrogens which allowed us 
to conclude that macrophage responses are deeply dependent on the specific micro-environmental 
conditions in which cells were prior to their activation.  
Concerning M2 macrophages despite the presence of a characteristic increase in IL10 production and 
decrease in IL1β, we also found that these cells release higher amounts of IL6 and TNF-α than Mᶲ and/or 
M1 macrophages. Again, we can speculate that previous exposure to an estrogen poor environment may 
change cytokine release from cells to a more pro-inflammatory profile. This is not surprisingly since 
macrophage can bear both M1 and M2 characteristics simultaneously, i.e., simultaneously express 
markers of both classical and alternative activation [203, 204] and thus M2 macrophages are able to 
secrete pro-inflammatory mediators in specific conditions [205, 206]. This suggests that changes of 
estrogen signalling and/or obesity may favor the polarization of M2 macrophages, not M1 macrophages. It 
is also possible that the M1/M2 system is just too simplified to adequately represent the heterogeneity of 
ATMs in obesity [207]. Moreover, this increase in the release of inflammatory cytokines by cells involved 
in inflammation resolution may exacerbate the inflammatory state that accompanies the decline of 
estrogens, namely in menopause. 
E2 significantly induced M1 release of IL10 and IL6 and decreased IL10, IL6, TNF-α and IL1β release by M2 
macrophages (Chapter III). As we can see, cytokine profiles do not follow the anti-inflammatory vs pro-
 CHAPTER V 
 
 
- 80 - 
inflammatory paradigm as expected for E2. If the endogenous activation of these cells in vivo is true, these 
findings may indicate the way that activated cells respond to coordinately regulate the development of 
inflammation after menopause. Besides, this finding could help explain why the time of the initiation is so 
important to the benefits of hormonal replacement therapy, as reported by some groups [208, 209]. Once 
exposed to an estrogen-deprived environment, re-exposure to E2 is unable to reverse the acquired pro-
inflammatory priming [210, 211].   
Moreover, all XEs (Chapter IV) significantly altered the pattern of cytokine release by M1 and M2 
macrophages, with a globally decreased of IL10 release by M2 macrophages. This may explain in part, why 
accumulation of XEs in vAT was negatively associated with plasma IL10, as we observed in our 
epidemiological study (Chapter II). Still, DEHP and DBP significantly increased IL1β release in M1 and M2 
macrophages, respectively. Active IL1β is produced by the cleavage of its inactive precursors by the 
protease caspase-1, which is activated by large multiprotein complexes named inflammasomes. 
Inflammasomes are central components of the innate immune system. An increase in AT IL1β of obese 
human, mainly in macrophages, has been reported, and it seems to be directly correlated with insulin 
resistance, features of metabolic syndrome and severity of T2D.  Further, compared to MHO phenotype, 
the vAT of MAO phenotype is characterized by higher inflammasome activation in macrophages 
infiltrating this tissue [212]. Therefore, we suggest that XEs may be a trigger for inflammasome activation 
and an additional factor for global metabolic dysfunction.  
Another unresolved issue concerns the exact mechanisms responsible for the observed results either for 
E2 or XEs. Until recently, most studies have focused on the classical, or genomic phase of steroid 
responses, leading to activation or repression of target gene expression [213]. These slow responses 
(hours to days) occur via a mechanism involving multiple syntheses and modifications of macromolecules, 
finally generating mature nucleic acid messengers and then proteins. In addition to classical signalling, E2-
ER can act within minutes or seconds via extranuclear and membrane-associated forms of the receptor. In 
a variety of cell types, membrane and extranuclear pools of ER, activate protein kinases that 
phosphorylate transcription factors to promote transcriptional action and usually initiate second 
messenger-triggered signal cascades which emanate from the plasma membrane [214, 215]. A central 
question pertaining to this field is the cell-specificity of ER action and the molecular mechanisms by which 
the receptor selectively activates or represses target genes persists. 
In order to address this question, we performed qPCR analysis in human macrophages which indeed 
revealed that some of the effects described above were mediated by either ERα or ERβ and/or by 
orchestrating NF-B, AP1, JNK or ERK signaling pathways. However, the detailed understanding of their 
mechanisms is incomplete and should therefore be the aim of future research. Most recently, it has been 
reported that an orphan G-protein-coupled receptor, GPER, serves as an ER and mediates E2 signaling from 
the membrane [104] or the endoplasmic reticulum [107]. There are examples of such initial rapid 
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responses for almost every class of steroid and related compounds [216]. We are now beginning to 
understand that steroid mimetics and steroid-targeted endocrine disruptors can also work via these rapid 
response pathways [143, 216].   
Although the activities of most environmental estrogens have been called “weak” because of their 
inability to initiate nuclear retention and transcriptional effects [143, 216], we demonstrated that they are 
quite potent initiators of signal cascades emanating from the membrane.  Moreover, the approach used 
by our study consisted of comparing E2/XEs and co-treatment with ER antagonists namely MPP (ERα 
inhibitor) and PHTPP (ERβ inhibitor), revealing the involvement of each receptor subtype in the described 
effects. Thus, as verified, the effect of treatment with ERs inhibitors varies according to cell type, thereby 
granting the possibility to selectively inhibit or stimulate estrogen-like actions in various tissues. 
Curiousely, our results provide proofs of ERβ functionality on macrophage subtypes. Concerning the issue 
of genomics or non-genomic nature of the results obtained here, knowing that the modulators we used 
are inhibitors of nuclear ERs and that the membrane ER is the classical nuclear receptor protein localized 
to cellular domain [217], we belive that in most cases, collaboration between extranuclear and nuclear 
receptor pools is necessary for final result obtained. 
Our study has limitations. Firstly, observational studies (Chapter II) do not prove causality, even when 
exposure is estimated on an individual level and does not allow for inferences regarding the temporality of 
events. One reason is that the concentration of XEs in plasma/AT at the time of clinical testing does not 
necessarily reflect the metabolic interference that may have developed some time in the past. In addition, 
the possibility exists that the observed associations are confounded by dietary factors, physical activity, or 
other covariables, which could not be addressed in this study. Secondly, our study was performed 
deliberately in a presumably more susceptible fraction of the population, i.e., obese subjects, and this 
means that our conclusions do not necessarily apply to healthy subjects. Finally, the associations for 
individual XEs were not corrected for multiple testingand therefore should be treated with caution. 
Regarding the study on human macrophages, technical reasons did not allow treating the macrophages 
with the same compounds evaluated in the epidemiological study. On the other hand, the current 
paradigm of macrophage activation has been extended from M1 vs M2 polarization to a spectrum model. 
Therefore, our phenotypes (Chapter III and IV) do not enterily reflet the complex biology of macrophage 
activation in the context of CVD. Also, we can not exclude that the differences observed in M1 and M2 
phenotypes in postmenopausal women may be due to confounding factors, other than estrogen loss, 
including aging, as well as we recognize that the previous exposure to a xenoestrogenic ambient may 
change cell responsiveness to these compounds ex vivo.   
Therefore, the results obtained in the present study provide new evidence of the effect of XEs on 
macrophage behavior and their mechanisms with relevance to the understanding of the action of 
environmental chemicals on the immune system and inflammation-associated diseases.  
 CHAPTER V 
 
 
- 82 - 
Because humans are simultaneously exposed to mixtures of different XEs that have the capacity to 
function as antagonists or agonists to a variety of hormones including estrogens, it is difficult to speculate 
about what kind of synergistic, additive or antagonistic actions might occur with XEs mixtures [218]. 
Importantly, biological effects of one XE can differ widely depending on the presence of another XE. 
Moreover, the statement of toxicology that “the dose makes poison” has recently been challenged by 
evidence that many XEs exhibit non-monotonic dose-response relationships in which biological effects are 
not directly proportional to concentration [219]. Humans are exposed daily to a variety of compounds, 
and it is thus likely that even if none reach an effective level, the combination or mixture of chemicals may 
become dangerous. Still, the fact that hormone-related effects of XEs are likely dependent on the 
endogenous hormonal milieu makes the issue even more complicated. Additionally, the combination of 
responses could add up to a continuous and sustained response, instead of an oscillating response typical 
of estrogen hormones, and lead to overstimulation resulting in disruption [6, 220]. This may explain 
differing potential hazards of exposure during times when endogenous estrogen levels are particularly 
high or low in either females or males in infancy, pubertal, reproductive and/or post-reproductive stages. 
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CONCLUDING REMARKS 
 
There has been great progress in terms of our understanding of how obesity-induced inflammation is 
regulated and how modulation of this process can regulate the development of obesity-induced metabolic 
abnormalities.  
A comprehensive consideration of the results presented in this dissertation allows us to provide novel 
insights regarding the ability of XEs to mediate obesity-associated inflammation and related metabolic 
abnormalities in a biomedicine dimension (Figure 4). We point out the need to identify biomarkers of XE 
exposure and discuss the suitability of plasma versus AT XEs measurement to assess whole body burdens 
of XEs. Indeed, the distribution and concentration of individual and total XEs differed between plasma, 
vAT and scAT, and the pattern of accumulation was different between pre- and postmenopausal women. 
In premenopausal women, although vAT XEs were more correlated with metabolic dysfunction, plasma 
XEs were the best predictors of inflammation and CVD risk. We also advanced that plasma XEs in these 
women may be released from vAT, as consequence of induction of local toxicity and AT dysfunction by 
XEs. In postmenopausal women, this AT dysfunction extends to scAT. More importantly, we advance that, 
other than associating with obesity grade or levels of AT accumulation, XE levels may help predict 
cardiometabolic risk. In this regard, evidence we have gathered allows us to state that, in our population, 
XEs may be good indicators of dysmetabolic obesity when premenopausal women are considered. 
However, it remains to be established if these findings can apply to other populations. Additionally, 
whether all these observations reflect causal pathways should be determined in longitudinal studies that 
may link exposure to specific chemicals with early disease development 
Although the CVD risk profile worsens in postmenopausal women, the causative mechanisms are 
incompletely understood. Herein, we advance a number of potential effects of XEs on obesity-derived 
complications including modulation of the inflammatory response and immune cell function.  
We present results showing that macrophage ERs are modulated by XEs, and may therefore be an 
important target to combat metabolic dysfunction. We further demonstrate that ERs are differently 
expressed among different stages of macrophage polarization, a feature that may be critical for 
determining their responsiveness to estrogenic stimuli. We also highlight that although ERα is expressed in 
substantially higher levels and most estrogen effects have been related to this isoform, ERβ may also play 
a role. Moreover, the co-treatment with either of the selective ERα and ERβ antagonists MPP and PHTPP, 
respectively, helped us understand the involvement of each receptor subtype in the described effects. The 
relationship between estrogens/XEs and inflammation on macrophages was exploited through 
determinations of intracellular transduction pathways, focusing on the interactions between 
inflammation-relevant effector kinases and transcription factors, and we point out that the previous 
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exposure to lack/decrease of estrogen signaling renders cells to a more pro-inflammatory situation, which 
might contribute to the manifestation of chronic inflammatory diseases.  
Evidently, XEs interact with E2 and estrogen-related signaling pathways leading to differential molecular 
effects, thus ultimately impacting in the physiological response of sensitive cells. Inflammation was at the 
center of our research interest, and we were able to demostrate that E2 and XEs impact on inflammation 
and immunological processes, which may bridge their effect on metabolism. However, it becomes evident 
from our research that XEs are more than estrogen mimetics, and that, not only their effects depend on 
cell type and the nature of the chemicals, but also on the presence of endogenous hormones, highlighting 
the variation of their effects throughout the life cycle. The implications of these observations relate to the 
fact that increasing the knowledge on how specific ER modulation may change macrophage behavior can 
constitute the basis for the development of therapeutic approaches with the aim of altering inflammatory 
status profile. Additionally, it would be interesting to study the effect of E2 and XEs in inflammatory and 
functional markers of AT as we understand they act as mediators that may help to explain the metabolic 
dysfunction associated with obesity. As our experimental results using inflammatory cells were based on 
short-term exposure to XEs, the investigation of the effects of long-term exposure to XEs and the 
underlying molecular mechanisms would also be worth exploring. 
Thus, basic and clinical researchers should be aware of the potential health impacts of these ubiquitous 
environmental chemicals, an understanding that depends both on the knowledge of the extent of the 
contamination of humans and other biological samples, but also on their effects and the mechanisms 
endowed. Even though the individuals we studied were assessed in adulthood, likely early life exposures 
to XEs do also occur, so the hypothesis on developmental determination of health and disease remains 
relevant. In this point of view, epidemiological studies integrating XEs into that hypothesis would be 
scientifically important, starting from in utero exposure (or even in prenatally in the subject’s parents), 
continuing to early fetal, childhood, adolescence, and adulthood periods, to evaluate how changes in 
exposure patterns during lifetime affect inflammation and cardiometabolic dysfunction. 
Another key point is introduced quoting the latest WHO report on endocrine disrupting chemicals 
,“…there is emerging evidence that many chemicals may act additively and, each at levels without 
individual effect, could act together to cause health problems” [221]. Rather than the old toxicological 
method of a single-exposure, dose-response approach using pure compounds, it is vital that new risk 
assessment procedures simulate more closely what occurs in nature. It is crucial to explore the effects of 
combinations of compounds or mixtures. 
Investigation on the action of XEs and other chemicals that alter metabolic function will open novel 
directions for the prevention and treatment of metabolic diseases, but will also reinforce the importance 
of international agreements to limit the release of XEs to minimize public health risks. These findings are 
both of public health and clinical significance in terms of screening and stratification based on XE 
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contaminations identifying those at greatest cardiometabolic risk for whom appropriate therapeutic or 
intervention strategies should be developed.  
From the amount of evidence being presenly accumulated it is becoming clearer that, negleting the novel 
and emerging knowledge about XEs and metabolic disease will have significant health impacts for the 
general population, as well as on the generations to come.  
 
 
Figure 4. Schematic representation of the proposed mechanisms through which XEs exposure may 
contribute to cardiometabolick dysfunction. CVD, cardiovascular disease; M2, alternatively-activated 
macrophages; MCP-1, monocyte chemotactic protein 1; scAT, subcutaneous adipose tissue; vAT, visceral 
adipose tissue; XEs, xenoestrogens. 
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